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Abstract
After almost 30 years of inertia in the field of sequencing, the emergence of a whole
range of so-called ”next-generation” sequencing technologies has revolutionized the way
we approach genomic and genetic research. Sequencing all 3 gigabases of a human
genome, once a costly task of 13 years of international efforts, can now be done within
a matter of days with a coverage of 30x and more, and comes with a price tag that
is affordable for a middle-sized lab. Among the different next-generation sequencing
machines developed over the course of the last 6 to 8 years, four instruments from three
different companies have established themselves on the market for human whole-genome
sequencing: Illumina’s HiSeq2000, Life Technologies’ SOLiD 4 and 5500xl SOLiD, and
Complete Genomics’ technology.
However, these next-generation sequencing platforms are still relatively new, and
a comprehensive comparative assessment of their performance is lacking. For this
purpose, the DNA of two tumor-normal pairs from medulloblastoma patients was
sequenced individually to 30x coverage on each of the four instruments. The resulting
data was analyzed with respect to its coverage distribution and biases over the genome,
in particular GC bias, and regions without coverage as well as specific genomic regions
were assessed. SNP calls on the different sequencing machines were compared, and
the benefits of combining read information from different instruments were evaluated.
Additionally, somatic mutations were analyzed.
The most striking result is the poor coverage of GC-rich regions by SOLiD 4 and 5500xl
SOLiD, discouraging their use in particular for methylation experiments and exome
sequencing. In contrast, Complete Genomics seems the least affected by GC content
and shows the most comprehensive coverage of many genomic regions, except for short
repeats. HiSeq2000 exhibits the most even genome-wide coverage distribution and the
least sample-to-sample variation, while consistently achieving the highest sensitivity in
SNP calling. A combination of read data from different technologies is shown to entail
limited improvement in most cases, and is advisable only for very specific applications.
Finally, the comparison of somatic variation confirms that calling somatic alterations is
still a big challenge, which is due in particular to low allele frequency. In summary, this
comparative study illustrates the assets and drawbacks of each individual machine and
can be used as a guide to find the most suitable platform for a specific experimental
goal.
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Zusammenfassung
In den letzten Jahren hat das Aufkommen von sogenannten ”next-generation-
sequencing” Hochdurchsatz-Technologien die Analysemo¨glichkeiten im Bereich der
Genomforschung vervielfacht. Die Sequenzierung der drei Gigabasen eines menschlichen
Genoms, ein bisher kostspieliger Vorgang, der unter internationalen Bemu¨hungen
13 Jahre in Anspruch nahm, ist nun innerhalb weniger Tage mit mehr als 30-
facher Abdeckung mo¨glich, und ist auch fu¨r Forschungseinrichtungen mittlerer Gro¨ße
erschwinglich geworden. Unter den bisher entwickelten next-generation-sequencing
Technologien haben sich vier Gera¨te von drei verschiedenen Firmen fu¨r den Einsatz
an menschlichen Genomen etabliert: Illuminas HiSeq2000, Life Technologies’ Solid 4
und 5500xl SOLiD Gera¨te, und Complete Genomics’ Technologie.
Allerdings sind diese Plattformen noch immer relativ neu, und eine umfassende
vergleichende Beurteilung ihrer Leistung fehlt. Zu diesem Zweck wurde die DNA zweier
Tumor-Normal Paare von Medulloblastom-Patienten auf jedem der vier Gera¨te einzeln
sequenziert. Die erhaltenen Daten wurden in Bezug auf die Verteilung der genomischen
Abdeckung und auf etwaige Verzerrungen, insbesondere in GC-reichen und GC-armen
Bereichen, untersucht. Nicht abgedeckte Bereiche und spezifische genomische Regionen
wurden ebenfalls begutachtet. Die auf den unterschiedlichen Plattformen bestimmten
SNPs wurden mithilfe eines Goldstandards verglichen und die etwaigen Vorteile einer
Kombination alignierter ”reads” verschiedener Technologien untersucht. Zusa¨tzlich
wurden somatische Mutationen analysiert.
Am hervorstechendsten ist die mangelhafte Abdeckung GC-reicher Genombereiche
durch SOLiD 4 and 5500xl SOLiD, die stark gegen die Verwendung dieser Plattformen,
insbesondere fu¨r Methylierungsexperimente und Exom-Sequenzierung spricht. Im
Gegensatz dazu scheint Complete Genomics am wenigsten vom GC-Gehalt der Sequenz
beeinflusst zu sein, und erreicht die umfassendste Abdeckung in vielen spezifischen
genomischen Regionen, mit Ausnahme von kurzen Repeats. HiSeq2000 weist die
gleichma¨ßigste genomweite Abdeckung und die geringste Variation zwischen den
Proben auf. Weiterhin erreicht HiSeq2000 stets die ho¨chste Sensitivita¨t bei der
SNP-Bestimmung. Eine Kombination der Daten verschiedener Technologien fu¨hrt
in den meisten Fa¨llen nicht zu einer wesentlichen Verbesserung und ist nur fu¨r
spezifische Anwendungen empfehlenswert. Schließlich besta¨tigt der Vergleich der
somatischen Mutationen, dass das Bestimmen somatischer Variation immer noch eine
große Herausforderung darstellt, vor allem aufgrund der niedrigen Allelfrequenzen.
Zusammenfassend zeigt diese Studie die Vor- und Nachteile der einzelnen Sequenzier-
gera¨te auf und kann als Orientierungshilfe dienen, um die fu¨r eine bestimmte
experimentelle Fragestellung am besten geeignete Plattform zu bestimmen.
iii

Contents
List of figures vii
List of abbreviations ix
1 Introduction 1
1.1 DNA sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 A short history of DNA sequencing . . . . . . . . . . . . . . . . 1
1.1.2 Next-generation sequencing . . . . . . . . . . . . . . . . . . . . 2
1.2 Applications of next-generation sequencing . . . . . . . . . . . . . . . . 15
1.2.1 Experimental applications . . . . . . . . . . . . . . . . . . . . . 15
1.2.2 Large-scale projects . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.2.3 DNA sequencing in cancer . . . . . . . . . . . . . . . . . . . . . 18
1.3 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.3.1 ”Big data” challenges . . . . . . . . . . . . . . . . . . . . . . . . 19
1.3.2 Analysis steps . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.4 Motivation and thesis outline . . . . . . . . . . . . . . . . . . . . . . . 24
1.4.1 Publication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2 Methods 27
2.1 Data generation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.1.1 Whole-genome sequencing . . . . . . . . . . . . . . . . . . . . . 27
2.2 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.1 Hardware . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.2 Read mapping . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.2.3 Coverage and downsampling . . . . . . . . . . . . . . . . . . . . 29
2.2.4 Conversion of Complete Genomics data . . . . . . . . . . . . . . 30
2.2.5 Combination of sequencing data from different technologies . . . 30
2.2.6 Coverage distribution and regions without coverage . . . . . . . 31
2.2.7 Functional regions . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.2.8 SNV calling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
v
Contents
2.2.9 Detection of somatic SNVs . . . . . . . . . . . . . . . . . . . . . 33
2.2.10 Detection of somatic indels . . . . . . . . . . . . . . . . . . . . . 36
2.2.11 Statistical tests . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.3 Data access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3 Results 39
3.1 GC bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.2 Coverage distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3 Coverage of genomic regions . . . . . . . . . . . . . . . . . . . . . . . . 50
3.4 Regions without coverage . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.5 SNP calling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.6 Combination of sequencing technologies . . . . . . . . . . . . . . . . . . 65
3.7 Somatic variation calling . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.7.1 Somatic SNVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.7.2 Somatic indels . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4 Discussion 81
4.1 Coverage assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.2 Variant detection comparison . . . . . . . . . . . . . . . . . . . . . . . 84
4.3 Evaluation of the detection of somatic mutations . . . . . . . . . . . . . 85
4.3.1 Somatic indel calling . . . . . . . . . . . . . . . . . . . . . . . . 87
4.4 Influence of mapping and detection software . . . . . . . . . . . . . . . 87
4.5 Conclusions and outlook . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5 Technical annex 93
Bibliography 97
Acknowledgements 109
Erkla¨rung 111
vi
List of Figures
1.1 Cost of sequencing a human-sized genome from 2001 to 2013 . . . . . . 3
1.2 Illumina sequencing, part I . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Illumina sequencing, part II . . . . . . . . . . . . . . . . . . . . . . . . 6
1.4 Complete Genomics sequencing setup . . . . . . . . . . . . . . . . . . . 8
1.5 The SOLiD sequencing process . . . . . . . . . . . . . . . . . . . . . . 10
1.6 Principles of two-base encoding in SOLiD sequencing platforms . . . . 11
1.7 Bisulfite sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.8 RNA-seq and ChIP-seq . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.9 Genomic alterations playing a role in cancer . . . . . . . . . . . . . . . 18
1.10 Typical analysis workflows for NGS data . . . . . . . . . . . . . . . . . 21
3.1 GC bias for each platform (Sample MB24) . . . . . . . . . . . . . . . . 41
3.2 GC bias for each platform (Sample BL24) . . . . . . . . . . . . . . . . 42
3.3 GC bias for each platform (Sample MB14) . . . . . . . . . . . . . . . . 43
3.4 GC bias for each platform (Sample BL14) . . . . . . . . . . . . . . . . 44
3.5 GC bias for HiSeq2000 with v2 chemistry versus HiSeq2000 with v3 chem-
istry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.6 Distribution of genome-wide base coverage . . . . . . . . . . . . . . . . 48
3.7 Cumulative genome-wide base coverage distribution . . . . . . . . . . . 48
3.8 Mean cumulative genome-wide base coverage distribution . . . . . . . . 49
3.9 Magnified view of mean cumulative genome-wide base coverage distribution 49
3.10 Mean fraction of uncovered bases across genomic elements (1) . . . . . 51
3.11 Visualization of read coverage for two exemplary genomic regions . . . 52
3.12 Mean fraction of uncovered bases across genomic elements (2) . . . . . 53
3.13 Mean fraction of uncovered bases across genomic elements for different
combinations of technologies . . . . . . . . . . . . . . . . . . . . . . . . 55
3.14 Size distribution of uncovered regions . . . . . . . . . . . . . . . . . . . 57
3.15 Distribution of Affymetrix array SNPs in genomic elements analyzed . 59
3.16 Distribution of Affymetrix array SNPs in repeat types analyzed . . . . 60
3.17 ROC curves for SNV calling (sample MB24) . . . . . . . . . . . . . . . 61
vii
List of Figures
3.18 Magnified view of ROC curves for SNV calling (sample MB24) . . . . . 61
3.19 ROC curves for SNV calling (sample BL24) . . . . . . . . . . . . . . . 62
3.20 Magnified view of ROC curves for SNV calling (sample BL24) . . . . . 62
3.21 ROC curves for SNV calling (sample MB14) . . . . . . . . . . . . . . . 63
3.22 Magnified view of ROC curves for SNV calling (sample MB14) . . . . . 63
3.23 ROC curves for SNV calling (sample BL14) . . . . . . . . . . . . . . . 64
3.24 Magnified view of ROC curves for SNV calling (sample BL14) . . . . . 64
3.25 Overlap of somatic SNVs called by different technologies (1) . . . . . . 67
3.26 Overlap of somatic SNVs called by different technologies (2) . . . . . . 68
3.27 Example of the ”flanking SNV” artifact seen in Life Technologies’ platforms 70
3.28 Overlap of somatic insertions and deletions found across platforms for
sample MB24 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
viii
List of abbreviations
AF allele frequency
AUC Area Under Curve
BAM Binary Alignment/Map
bp base pairs
BWT Burrows Wheeler Transform
CE capillary electrophoresis
CGI CpG island
chr chromosome
ddNTP dideoxynucleotide triphosphate
del deletion
DNBs DNA nanoballs
FN False Negative
FP False Positive
Gb Gigabase
HGP Human Genome Project
ICGC International Cancer Genome Consortium
IGV Integrative Genomics Viewer
indel insertion or deletion
ins insertion
kb kilobase
LINE Long Interspersed Nuclear Element
LTR Long Terminal Repeat
Mb Megabase
NGS next-generation sequencing
PCR Polymerase Chain Reaction
RAM Random-Access Memory
RC Rolling Circle
ROC Receiver Operating Characteristic
rRNA ribosomal RNA
scRNA small cytoplasmic RNA
SINE Short Interspersed Nuclear Element
snRNA small nuclear RNA
srpRNA signal recognition particle RNA
SNP Single Nucleotide Polymorphism
SNV Single Nucleotide Variant
TF Transcription Factor
TN True Negative
TP True Positive
tRNA transfer RNA
VCF Variant Call Format
ix

1 Introduction
1.1 DNA sequencing
1.1.1 A short history of DNA sequencing
Sixty years after the structure of DNA was determined by James Watson and Francis
Crick [1], a discovery which was honored with the Nobel Prize in 19621, the methods
for the determination of individual DNA sequences have been subject to monumental
transformation. The first DNA sequencing methods were published in the late seven-
ties, the ”Sanger sequencing” method by Sanger and Coulson [2, 3] quickly replacing
the earlier technique by Maxam-Gilbert [4] as the latter used hazardous compounds
and had a generally more complex technical setup [5]. The Nobel prize for chemistry
was awarded for both methods in 19802.
In the 30 years following the publication of the Sanger method, this sequencing
technique was the only broadly used protocol. The main characteristic of the method is
the use of chain-terminating dideoxynucleotides (ddNTPs). The most recent protocol
variant [6, 7] involves fluorescently labeled ddNTPs, and DNA sequence is read-out
by capillary electrophoresis (CE). Initially, the DNA fragment to sequence is cloned
into a plasmid vector and amplified through its transfection into bacterial cells. The
resulting DNA is isolated and then replicated in vitro in four different reactions (each
assessing the positions of one of the four DNA bases) using a DNA primer and a
DNA polymerase. Each reaction takes place in presence of normal deoxynucleoside
triphosphates as well as one of the four fluorescently labeled, chain-terminating
dideoxynucleotides (either ddATP, ddCTP, ddGTP, or ddTTP). Because these do not
contain a 3’-hydroxyl group, the replication is stopped upon their incorporation into
the DNA chain. Each of the four replication reactions generates DNA fragment copies
of different sizes, each of them terminated by a fluorescent ddNTP. These are then
size-sorted by capillary electrophoresis, and the fluorescent patterns are read out via
laser detectors, allowing the reconstruction of the underlying DNA sequence.
1http://www.nobelprize.org/nobel_prizes/medicine/laureates/
2http://www.nobelprize.org/nobel_prizes/chemistry/laureates/
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Capillary electrophoresis was used for the initial sequencing of the full human genome.
Launched in 1990, the completion of the Human Genome Project (HGP) took more
than a decade, using up a budget of approximately 3 billion US dollars - essentially
a dollar per base pair. In early 2001, the first draft human genome sequences were
reported by the International Human Genome Sequencing Consortium [8] and by the
company Celera Genomics [9]. In 2003, the HGP declared the human genome sequence
”essentially complete”, covering 99% of the euchromatic genome [10]. Regular updates
to the assembly are given by the Genome Reference Consortium3.
Establishing a human reference sequence had a massive impact on the research commu-
nity, highlighting that all previous knowledge was extremely limited and that the human
genome and its functions were far more complex than assumed [11]. As an example,
protein-coding sequence was found to make up only 1-1.5% of the genome, which is in
remarkable contrast to previous estimates, while the importance of gene regulation was
strongly underestimated, as was the role of non-coding components like small RNAs.
The sequence of the human genome enabled far more comprehensive and systematic
approaches in the field of genetics and genomics, and its importance to the research
community is largely reflected in the number of queries received by the main genome
data servers, the European Bioinformatics Institute (EBI) alone recording around 9
million requests per day in 2012 [12].
1.1.2 Next-generation sequencing
The establishment of the human genome sequence was only the start of a major shift in
the field. The year 2005 marked the advent of massively parallel, or ”next-generation”
sequencing. Both the company 454 Life Sciences [14] and the lab of George Church at
Harvard Medical School [15] published new protocols which used a decreased reaction
volume while allowing an impressive increase in the total number of DNA fragments
assessed. In 2006 and 2007, respectively, the companies Illumina and Applied Biosys-
tems (now Life Technologies) introduced novel next-generation sequencing instruments
based on sequencing by synthesis and sequencing by ligation, respectively. Their
capacity was orders of magnitude greater than that of previous methods, and provided
the basis for an extremely sharp drop in sequencing cost (Figure 1.1) and the appoint-
ment of next-generation sequencing as ”method of the year” by Nature Methods [16],
emphasizing its relevance for life science research. Soon afterwards, a number of
human whole genomes were sequenced on different platforms [17–20]. A project that
had previously needed over ten years to complete with Sanger sequencing could now
be completed in a fraction of the time, and was therefore welcomed by the research
3http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/
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Figure 1.1: The cost of sequencing a human-sized genome from 2001 to 2013, as
taken from the National Human Genome Research Institute of the USA
(http://www.genome.gov/sequencingcosts/) on May 23rd, 2013. Costs
for downstream analysis are not included. Moore’s law (hypothetical data
shown on the graph) reflects the observation that the processing power
of computer hardware doubles roughly every two years. It is generally
used as a way to assess technology improvements [13]. The sudden drop
in sequencing costs and outperformance of Moore’s law from January
2008 onwards corresponds to sequencing centers shifting from the Sanger
sequencing method to next-generation sequencing platforms.
3
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community as a novel, faster way to shed light onto our understanding of disease
and treatment, and the genetic and epigenetic processes that make up the human being.
This cost-effective, faster way to sequence was mainly attained through the automation
of a time-limiting and error-prone step of Sanger sequencing: the preparation of
cloning libraries. Instead of amplifying the DNA to be sequenced in bacteria in vivo,
as described above in section 1.1.1, it is randomly fragmented, adaptor-ligated, and
then selectively amplified using PCR, with the positive side effect of avoiding cloning
bias. Additionally, this enables the sequencing and detection of low-abundance reads
and mutations, as the sequencing templates are derived from a single molecule.
The automation and reduction of the reaction volume result in a dramatically higher
throughput. As an example, up-to-date whole-genome next-generation sequencing ma-
chines like the Illumina HiSeq2000 attain a throughput of roughly 55 Gb per day4, while
”traditional” CE-based Sanger sequencing produces around 1.35 Mb per day [6], over
four orders of magnitude less. Currently, four different platforms from three companies
are established for human whole-genome sequencing: the HiSeq2000 by Illumina (and
the HiSeq2500, which was recently released) [17], Complete Genomics’ platform [20],
and the SOLiD 4 and 5500xl SOLiD by Life Technologies [18].
Illumina sequencers
Illumina is currently considered as ”the most widely used sequencing technology” [21]
and has released a number of upgraded platforms since its first one, the Illumina
(Solexa) Genome Analyzer, was introduced to the market in 2006. Illumina sequencers
use a polymerase-based sequencing-by-synthesis method [17].
The sequencing takes place in a glass flowcell (two for HiSeq2000 and upwards), each
divided into eight lanes. Each separate lane can contain different sequencing material
if needed. An overview of the steps followed is given in Figure 1.2 and 1.3. The surface
of the flowcell is covered with covalently attached oligonucleotides. These are used
to fix single-stranded DNA fragments onto the surface via end-ligated adapters. In
order to later reach a sufficient signal during the sequencing step, these fragments are
then replicated via bridge amplification PCR [17] and form so-called clusters of one
and the same DNA fragment. The clusters are then exposed to fluorescently labeled
nucleotides which bear a chemically inactivated 3’-hydroxyl group to prevent the incor-
poration of more than one base at a time. In the next step, the color emitted by each
cluster is recorded and assigned to the corresponding nucleotide, whose 3’ end is then
4http://www.illumina.com/systems/hiseq_comparison.ilmn
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”unblocked”. After this, the full cycle is repeated, and the sequence of each cluster
of identical fragments is optically read out by a CCD camera, base by base until the
maximum read length is reached. Currently, a read length of 2 x 100 bp can be reached
with the Illumina HiSeq20005 when in paired-end mode, i.e., when both ends of the
fragments are sequenced, and roughly 11 days are needed per run.
Figure 1.2: Preparation of the DNA clusters to be sequenced on an Illumina flow cell. In-
dividual DNA fragments with ligated adapters are attached onto the surface
and replicated into clusters of the same fragment via bridge amplification.
Figure taken from Mardis et al. [22].
5See footnote 4
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Figure 1.3: Illumina sequencing step. Fluorescently labeled nucleotides with a
chemically blocked 3’-OH group are incorporated into the DNA fragment
clusters. After read-out of the emitted fluorescence and assignment to the
corresponding nucleotide, the 3’ end of the incorporated nucleotide is un-
blocked and the cycle is repeated anew. Figure taken from Mardis et al. [22].
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Complete Genomics
Complete Genomics Inc. was established in 2006 and published its first human whole-
genome sequences in late 2009 [20]. Unlike other companies which offer sequencing
instruments for sale, Complete Genomics is a sequencing facility selling sequencing
and analysis as a proprietary service. The company focuses on human whole-genome
sequencing and has developed both a novel sequencing method and software for the
downstream analysis. They offer a Standard Sequencing Service as well as a Cancer
Sequencing Service6 and provide customers with reads and mapping as well as variants
like SNVs, indels, and copy number variants.
Complete Genomics’ sequencing relies on hybridization and ligation using a protocol
allowing for extremely densely packed DNA fragments, and thus needing only very
small reagent volumes. An overview of the process is given in Figure 1.4 (A). The
fragments first go through a series of adapter insertions using restriction enzymes
and are then circularized (Figure 1.4 (B)). The circularized sequencing fragments are
around 400 bases long and contain 2 x 35 (10 + 10 + 10 + 5) bases of fragmented
mate-pair reads from the original genomic DNA fragment. The reason for these short
read fractions is that the sequencing by ligation approach as it is carried out by
Complete Genomics does not allow for longer readouts7.
The circularized templates are subsequently amplified with Φ29 polymerase, which
generates hundreds of tandem copies of the fragments, called DNA nanoballs or DNBs
(Figure 1.4 (C)), which are less than 200 nm in diameter [23]. These are then placed
onto a photolithographically patterned silicon chip with aminosilane active sites placed
1 µm apart. Up to 3 billion DNBs can be placed on one 25 x 75 mm silicon substrate [23].
Each DNB site is then sequenced via combinatorial Probe-Anchor Ligation (cPAL).
Using a set of standard and degenerate anchors, and pools of probes with four different
fluorescent dye labels (one for each base), each position is read out independently after
hybridization and ligation of the corresponding probe (Figure 1.4 (D)). The anchor
and probe are washed away after each readout step. The fact that bases are read
independently and in no fixed order avoids an accumulation of errors that can occur
on other sequencing platforms.
6Complete Genomics Technology White Paper, http://www.completegenomics.com/
knowledge-center/whitepapers/
7See footnote 6
7
1 Introduction
Complete Genomics’ standard genome coverage is generally higher than that of other
platforms (50-80x vs. 30x), but the turnaround time for their service is about 90 to 120
days8.
Figure 1.4: Complete Genomics sequencing setup. (A) Overview of the sequencing
steps. (B) Adapter insertions into the genomic fragment to be sequenced.
(C) Generation of DNA nanoballs via PCR and view of the silicon chips
used for sequencing. (D) Example of combinatorial Probe-Anchor Ligation
sequencing. Figure taken from Drmanac et al. [20].
8http://www.completegenomics.com/FAQs/Complete-Genomics-Service-General-Information/
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SOLiD sequencers
First introduced in 2007, the SOLiD acronym stands for Sequencing by Oligo Ligation
and Detection [18]. The DNA fragments to be sequenced are coupled to small magnetic
beads covered with oligo adapters, and are subsequently amplified via emulsion
PCR [24]. The beads are then attached to a glass slide inside a flow cell. For the 5500xl
SOLiD platform, beads are replaced with direct amplification on the flow chips9. Each
SOLiD instrument possesses 2 of these flow chips that can each take up to 8 (SOLiD
4)10 or 12 (5500xl SOLiD)11 separate samples per run.
The SOLiD sequencing process consists of multiple sequencing rounds, as exemplified
in Figure 1.5. After the annealing of a universal primer to the adapter, fluorescently
labeled, semi-degenerate octamers are sequentially ligated to the DNA template. The
distinctive feature of SOLiD platforms is their primary output in so-called ”color
space” (as opposed to base space)12, an encoded form of the nucleotide sequence where
four colors are used to represent 16 combinations of two bases, as shown in Figure 1.6.
After the ligation of an octamer, the color emitted is recorded and the fluorophore
and the end of the octamer are chemically cleaved to allow for the next ligation cycle.
After a defined number of ligation cycles, the complementary strand is removed and a
new sequencing round is started using a primer annealed one base further upstream.
This means that the positions assessed by the octamers change in each round, as can
be seen in Figure 1.5, and the sequencing stops once every base has been probed twice,
i.e. is represented by two associated fluorophore colors.
The color-space data can then be decoded given prior knowledge of the leading base,
usually the last base of the adapter. This strategy, called two-base encoding, allows to
recognize certain sequencing errors, as depicted in Figure 1.5(b). Most importantly, a
single point mutation in the DNA fragment sequenced will result in two adjacent color
changes, while an error in color space will change the entire decoding of the remainder
of the DNA fragment when assessed individually without a reference sequence. This
property makes it easier to distinguish actual sequence changes in base space from
sequencing errors in color space.
9http://tools.invitrogen.com/content/sfs/brochures/CO111759_5500_W_prelim_spec_
sheet_FLR.pdf
10http://www3.appliedbiosystems.com/cms/groups/global_marketing_group/documents/
generaldocuments/cms_078637.pdf
11http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/
solid-next-generation-sequencing/next-generation-systems.html
12http://marketing.appliedbiosystems.com/images/Product_Microsites/Solid_Knowledge_
MS/pdf/CSHL_Fu.pdf
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Currently, paired-end read lengths of 50 bp + 35 bp, and 75 bp + 35 bp can be reached
with the SOLiD 4 and 5500xl SOLiD platforms, respectively, and run times range from
10-20 days.
Figure 1.5: The SOLiD sequencing process. (a) Each sequencing round starts with
the annealing of a universal primer and then the subsequent ligation of
the fluorescently labeled octamers matching the underlying DNA sequence.
The color of the fluorescent tag stands for a combination of the two non-
degenerate bases of the octamer, as illustrated in Figure 1.6. After a defined
number of ligation cycles, a new sequencing round is started with a primer
placed one base further to the left. This is repeated until every base has
been probed twice, as emphasized by the blue rectangles. (b) An example
of possible color changes within the sequence and their associated meaning.
Figure taken from Mardis et al. [25].
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Figure 1.6: Principles of two-base encoding and color space used in SOLiD sequencing
platforms. Each color stands for a succession of two bases. As a consequence,
each base is interrogated twice. The alignment to a reference sequence allows
the conversion back to base space and the identification of sequence variation
and sequencing errors. Figure taken from Mardis et al. [22].
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Known issues
One of the most prominent characteristics of next-generation sequencing is the short
read length. While Sanger-based capillary sequencers produce read lengths in the
range of 650 to 800 bp, the first Illumina and SOLiD instruments reached a read
length of only 35-36 bp [25]. Although the accessible read length is rapidly growing
among next-generation platforms, and even further among third-generation sequencing
instruments (see section 1.1.2 below), a short read length is an obstacle to downstream
analysis. The assembly of a genome from its sequenced reads, as it was performed
with Sanger sequencing and the human genome (see section 1.1.1) is a challenging
task with short reads, as this increases potential similarity between reads even if they
do not belong to overlapping regions of the genome of interest [26]. For organisms
with an already available genome sequence, this has led to the general practice of
mapping reads onto the reference sequence instead of assembling them, as described
in section 1.3.2. Both mapping and assembly processes can be improved by using
paired-end reads, i.e. by sequencing both ends of the DNA fragment instead of one
end only13. The information about the distance between these two reads is stored to
decrease ambiguities during mapping or assembly.
Short read length is a problem in particular for DNA repeat regions, which represent
a large fraction of many genomes, and especially of the human genome with a repeat
content of at least 50% [27]. Repetitive elements take many forms, from just a few
to millions of copies, and from just a few bases in length to millions of bases. Long
regarded as ”junk DNA”, it has been found that repeats have a function in human
evolution, can influence gene expression [28, 29], and play a role in a number of
diseases [30–32]. In addition, short tandem repeats are used in genealogy and forensics
as DNA fingerprints [33].
Another issue is known as ”phasing noise” or ”loss of synchrony”. It describes the
substitution errors that arise when clonally amplified DNA fragments which are
fluorescently probed at the same time - as is the case in the Illumina or SOLiD
protocols - get ”out of phase”. It is assumed that certain sequence patterns trigger
loss of synchrony [34]. An additional factor which leads to low base quality at the read
end is the fading of fluorescent signal intensity in higher cycle numbers, an issue which
is supposedly caused by the limited yield of the elongation reaction [35].
Finally, next-generation sequencing is affected by polymerase-induced biases, leading
to a non-uniform representation of the genome. This is especially problematic for
13http://www.illumina.com/Documents/products/Illumina_Sequencing_Introduction.pdf
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quantitative sequencing experiments like RNA-seq or copy number estimation, but can
also lead to missed or erroneous variant calls.
During library preparation, i.e. the generation of fragments of DNA to be sequenced,
a short PCR step is used to select for fragments successfully ligated to adapters [36].
Libraries with too little starting material or with a great variance in starting fragment
size will result in a major fraction of duplicated fragments [37]. As long as this fraction
is small, it is sufficient to remove reads or read pairs mapping at the exact same position.
The most prominent PCR-induced bias, which also arises during library preparation,
is known as GC bias, i.e. the underrepresentation of GC-rich, but also GC-poor
fragments, leading to decreased coverage in the corresponding genomic regions [38,39].
Even though regions with a highly unbalanced base composition represent only a small
part of the human genome, GC-rich regions have been shown to correlate with high
gene content [40–42] and are frequently part of gene promoters [43].
The base pair error rate of next-generation sequencers is assumed to be higher than the
error rate of Sanger sequencing. The Sanger error rates found in the literature range
from 0.001% to 1%, depending on the read post-processing software [44]. Illumina
error rates are usually found to be between 0.05% and 1%, while the error rates from
Life Technologies’ instruments are claimed by the company to be around 0.075% [45].
Complete Genomics have never released a base pair error rate14, but state a variant call
error rate of 1 variant per 100 kb [20].
Third-generation sequencing
A new generation of sequencing machines is currently emerging, denoted as ”next-
next-generation”, ”third-generation” or ”benchtop sequencing”. While some authors
restrict the term to single-molecule sequencing protocols (as opposed to protocols
using PCR-replicated libraries), it is widely used for the platforms introduced after
the ultra-parallel whole-genome sequencing machines reviewed in this thesis. Beside
the Illumina MiSeq, platforms like the Ion Torrent and Ion Proton [46] or the Pacific
Biosciences sequencer [47] introduce innovative protocols that eventually promise
longer reads - from 150 bp to over 1kb - and faster turnaround times (between a few
hours and a day) at a lower overall cost [48]. These methods are still in their infancy
and not yet capable of sequencing a full human genome in a single run, but Life
Technologies recently reported ”not seeing the end of capacity” for Ion Torrent and
14based on personal communication with Complete Genomics
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Proton platforms [21].
The Ion sequencers are sequencing-by-synthesis machines based on semiconductor
technology and function much like a pH-meter. They detect the proton that is released
upon incorporation of a nucleotide into the growing strand, and thus do not require
light, scanning and cameras for the detection process, saving a significant amount of
time. The throughput has increased from 20-50 Mb/run on the first chips to 1 Gb/run
(with a run time of 2-3 hours) on the current 318 chip. However, the platform still
uses a ”wash-and-scan” technology analogous to the second generation platforms.
The MiSeq, Illumina’s new benchtop sequencer, is based on the sequencing-by-synthesis
chemistry already in use in the previous Illumina machines. However, it is designed to
have shorter run times and less throughput (1 Gb/run with a run time of roughly a
day), attained through a smaller flow cell and faster microfluidics [49], and is geared
towards clinical diagnostics and smaller laboratories.
Pacific Biosciences takes an entirely different approach, introducing single-molecule
real-time (SMRT) sequencing. This is the first approach to observe not a high amount
of replicated fragments, but a single DNA molecule as it is synthesized by DNA
polymerase. This allows to circumvent many of the biases described earlier on, and
even allows sequencing long stretches of short repeats [50]. This setup drastically
reduces the sample preparation time and the amount of reagents needed, does not
require time-intensive steps like scanning or washing, and allows significantly longer
read-outs (over 1 kb). Pacific Biosciences sequencing uses metal chips with nanoscale
wells, termed zero-mode waveguides, which contain a DNA polymerase fixed at the
bottom. The small volume allows the detection of the incorporation of a single
fluorescently labeled nucleotide into the growing DNA strand. Because the fluorescent
dye is attached to the phosphate group, it is cleaved upon incorporation, and diffuses
out of the well and into the dark quickly. The kinetic data of the polymerase can also
be used to detect DNA modifications like methylation [51, 52]. Although the system
allows real-time sequencing in a matter of hours, the throughput is currently low at
only of 100 Mb/run, and the error rates are extremely high (12-13%), mostly consisting
of insertions and deletions [48].
Another company which is developing a sequencing platform based on a single-molecule
approach is Oxford Nanopore [53]. However, their device is still in the development
phase and is not on the market yet.
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1.2 Applications of next-generation sequencing
1.2.1 Experimental applications
The classical use of next-generation methods is the sequencing or re-sequencing of whole
genomes, but the high throughput attained has allowed the development of a wide range
of other experimental applications, gradually replacing genomic chips and arrays [54].
Beyond the discovery of point mutations and indels [55], whole-genome sequencing has
been used to detect copy number variation [56, 57], structural variation [58], or DNA
methylation using bisulfite conversion [59] (Figure 1.7). Next-generation sequencing
is also opening the field of metagenomics [60] and enables the fast assembly of small
genomes like the enterohemorrhagic E. coli strain which led to a severe outbreak of
foodborne illness in Germany in 2011 [61].
RNA sequencing is used as a means to evaluate gene expression [62–64] (Figure 1.8 (a))
or for the analysis of non-coding small RNAs [65,66]. A broad range of application also
uses next-generation sequencing techniques to target specific parts of the genome, the
most widely used being exome sequencing [67, 68] and DNA enrichment procedures to
target DNA-protein interactions, chromatin structure or epigenetic marks, like ChiP-seq
[69,70] or MeDIP-seq [71] (Figure 1.8 (b)). The latter are both adaptions of DNA chip
protocols to next-generation sequencing. A more complete overview of experimental
applications can be found in Shendure et al. 2012 [72].
Next-generation sequencing in the clinic
Being able to sequence a human genome in a matter of days, at a non-prohibitive cost,
makes next-generation sequencing applications interesting not only for fundamental
research, but also in a clinical diagnostics setting. The idea is to use the information
gained through whole-genome sequencing of patients for personalized medicine, i.e.
for an assessment of expected patient response to different therapy options, and for
an assessment of disease risk [74]. However, the requirements to fulfill are radically
different for a ”clinical-grade” whole genome. Up to now, there is no infrastructure
and no standards or guidelines established for this [75], and sequencing data does not
always lead to clear conclusions that can be immediately put into action [76], although
disease gene panels exist for a small number of genes and for diseases with known
genetic causes. In addition, the psychological aspect should not be left out, as whole-
genome sequencing may incidentally unveil high risk factors for late-onset diseases with
no available treatment, like Alzheimer’s or Huntington’s disease, or dementia [75, 77].
Also, there is a certain chance of false positives which should not be disregarded as this
may have a severe impact on patients lives [78]. Pilot studies for integrating whole-
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Figure 1.7: Bisulfite sequencing is used to analyze DNA methylation. DNA is subjected
to a bisulfite treatment that converts unmethylated cytosines to uracil by
deamination, but leaves methylated cytosines intact. In a subsequent PCR
step, uracils are then converted to thymines, as they are thymine analogs.
Figure taken from [73].
Figure 1.8: (a) RNA-seq for the analysis of gene expression. Coding RNA is isolated,
usually by targeting its poly-A tail, and is then reverse transcribed to cDNA.
The latter is then sequenced on a next-generation platform. After align-
ment, the sequenced reads can be used to quantitate the RNA content of
the sample. Figure taken from [69]. (b) Chromatin immunoprecipitation
(ChIP) is a method to analyze DNA-protein interactions. It is commonly
used to locate the DNA binding sites of transcription factors, histones, or
modified histones. The DNA fragments bound to the protein of interest
are isolated via immunoprecipitation, and are then sequenced with a next-
generation platform. A similar technique can be employed to identify sites
of DNA methylation. Figure adapted from [70].
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genome sequencing into clinical practice are underway [79, 80], and initiatives like the
DKFZ HIPO project15 promise to build a first scaffold for personalized medicine in
oncology.
1.2.2 Large-scale projects
Sharply sinking costs and increased throughput have given rise to a number of
prestigious large-scale international genomic projects, e.g., the 1000 Genomes
project [55,81] and the International Cancer Genome Consortium (ICGC) project [82],
both launched in 2008. The recently completed Encyclopedia of DNA Elements
(ENCODE) project [83, 84], although already planned in 2003, equally profited from
the development of next-generation sequencing. All projects are aiming at sequencing
a high number of genomes, either to investigate human genetic variation in healthy
individuals (1000 genomes project) or cancer patients (ICGC), or to catalog functional
elements of the human genome (ENCODE).
The 1000 genomes project aims to sequence entire genomes of a high number of
individuals from different populations in order to assess their genetic diversity. While
the initial project plan involved 1,000 individuals, this goal was extended to sequence
around 2,500 samples, the sequencing results of which will be made available publicly.
In order to lower costs, sequencing takes place at a comparatively low coverage of 4x.
This is not enough to obtain a complete genotype of each individual, but allows to
detect most genetic variants with a population frequency above 1%. These can then in
turn be used for studies linking genetic variation and disease.
The International Cancer Genome Consortium is composed of 47 project teams from
Asia, Australia, Europe and the Americas, and leads large-scale cancer genome studies
of 50 cancer types. For each cancer type, the whole genome, the transcriptome and
the epigenome of 500 patients are currently being sequenced to unravel oncogenic
variation, which will allow to search for cancer origin and classify cancer subtypes in
order to predict clinical outcome and develop better, individually tailored therapies.
The ENCODE project integrated a number of different technologies with the goal
to attribute biochemical functions to genomic elements, especially outside the long
established protein-coding regions, challenging the widespread assumption that the
human genome predominantly consists of so-called ”junk DNA”. The insights from
15http://www.bio-pro.de/magazin/index.html?lang=en&artikelid=/artikel/09012/index.
html
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Figure 1.9: Genomic alterations playing a role in cancer, as seen in next-generation
sequencing data. Figure taken from Meyerson et al. [86].
the ENCODE project were recently published simultaneously in 32 papers16, the tenor
being that over three quarters of the human genome can actually be transcribed. Using,
among others, next-generation sequencing techniques like ChIP-seq and RNA-seq (see
section 1.2.1), the ENCODE project studied different cell types and investigated the
function, expression levels and localization of transcribed RNA, as well as factors
influencing transcription, like transcription factor binding, histone modifications, DNA
methylation, or general chromatin accessibility.
1.2.3 DNA sequencing in cancer
The availability of next-generation sequencing methods has lead to profound changes
across many research fields. The search for the determinants of cancer has particularly
benefited from the possibility of sequencing samples from hundreds of cancer patients,
as is the case within the ICGC project (see previous section 1.2.2), as cancer is a
consequence of often massive genomic alterations [85].
Figure 1.9 illustrates many of the changes that can occur in cancer genomes and the
way they translate to whole-genome next-generation sequencing data: from simple
point mutations to insertions and deletions, copy number changes, chromosomal
translocations, or insertion of non-human, e.g. viral [87], sequence. In addition, epi-
genetic changes are also known to play an important role in cancer development [88].
These alterations are usually somatic, i.e. acquired in non-germ cells over decades, and
16http://www.encodeproject.org
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are subject to natural selection. A tumor arises when cells carry unrepaired changes
conferring a selective advantage, allowing them to proliferate [89]. These changes are
termed ”driver mutations”, as opposed to ”passenger mutations” that do not have an
impact on cancer development.
Detecting mutations in cancer genomes is a challenge of its own. The search for
somatic mutations normally involves the sequencing of a normal control tissue,
so that two full genomes need to be sequenced per patient. Also, as cancer cells
usually originate from several phases of clonal expansion, their genomes can be highly
heterogeneous and may carry different driver mutations in parallel [90]. In addition,
cancer tissue usually contains a certain fraction of normal, non-malignant cells, and
copy number variation is a rather common event [86]. As a consequence, the allele fre-
quency of somatic mutations is often drastically lower than variant allele frequencies in
normal tissue, which makes them harder to detect and requires a high sequencing depth.
The ultimate goal of mutation detection in cancer is to advance diagnostics, prognos-
tics, and treatment. As the treatments themselves are extremely aggressive, knowing
driver mutations in advance allows for targeted therapy, meaning that patients likely to
benefit from it can be identified upfront, whereas patients likely to be unresponsive will
be spared from ineffective therapy. Tailored treatments often target mutated protein
products, so that driver mutation detection can be used for drug discovery [91]. The
most prominent example is imatinib, an inhibitor of a constitutively active tyrosine
kinase in chronic myeloid leukemia, which has greatly improved the treatment of the
disease [92].
1.3 Data analysis
1.3.1 ”Big data” challenges
For a long time, the limiting factors for whole-genome sequencing have been cost and
throughput, and sequencing was therefore only performed by large research centers
like the Wellcome Trust Sanger Institute in the UK. At the National Human Genome
Research Institute in the USA, a ”Billion Basepair Celebration” was held in 1999
to celebrate the billionth base pair sequenced in the Human Genome Project17, a
number which can now be reached in a matter of hours. Meanwhile, the unprecedented
throughput and sharp drop in sequencing costs allows even smaller labs to afford
next-generation sequencing machines, leading to an unparalleled flood of genomic data.
17http://www.genome.gov/10002105
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Often termed ”big data”, this phenomenon gives rise to a number of challenges related
to data storage, transfer, processing and analysis, and also has implications for patient
data privacy.
The output generated by next-generation sequencing machines has for some while
outpaced Moore’s law (Figure 1.1). While the transistor density on an integrated
circuit is growing by a factor of 2 roughly every one to two years [93], for next-
generation sequencing data, this has reached a factor of 10 every year since 2002 [94].
The European Bioinformatics Institute (EBI) alone, which runs one of the largest
public repositories, stores two petabytes of next-generation sequencing data, with this
amount doubling every twelve months [95]. As a consequence, new ways of storing,
transferring, and analyzing data are needed. Some answers may lie in the design of
smarter algorithms [96] and in the circumvention of data transfer needs, for example
through cloud-based solutions containing both databases and analysis software. While
the latter are beneficial especially to smaller research groups and institutions by
eliminating the need for a computational infrastructure of their own, there may be
access and privacy issues [12].
Privacy is a relatively new concern in this respect [97]. While genomic research has been
heavily relying on raw, usually anonymized data shared via internet databases [98],
some of which are open-access, a number of recent studies highlight that this may not
be safe enough to protect the identity of study participants [99]. Particular attention
was raised by Gymrek et al. for their recent study in which short tandem repeats on
the Y chromosome were used in combination with publicly available information from
genetic genealogy databases in order to identify sequenced individuals [100].
1.3.2 Analysis steps
The advent of next-generation sequencing required a whole new infrastructure for the
downstream analysis of the machine’s output, as previous solutions were not suitable
any more, being too slow for the available throughput, and not adapted to the shorter
read lengths or to new experiment designs (section 1.2.1).
Figure 1.10 shows typical analysis workflows for next-generation sequencing data. The
instruments initially produce so-called ”reads”, i.e. short sequence fragments, and
associated base quality values derived from base calling procedures, for example from
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Figure 1.10: Typical analysis workflows for NGS data. DNA or RNA is fragmented,
pre-processed and sequenced. The sequencing machine generates so-called
reads, i.e. short stretches of read-out sequence. Each base is assigned
a base quality. The reads are then aligned to a reference genome (if
available) and the resulting information is stored in a standardized BAM
file. Coverage is then evaluated to assess the success of the experiment,
and the mapped data is analyzed according to the chosen experiment type:
the most common being variant calling (SNVs, indels, or copy number
variation for example), measurement of gene expression, or analyses of
genomic regions previously enriched according to a certain criteria, e.g.,
CpG methylation, transcriptor factor binding, or histone binding, among
others.
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fluorescent readouts [101]. The standard format for base quality is Phred scores [102]
which are computed as follows:
QPhred = −10 · log10P (error)
A base quality score of 20, for example, amounts to an error probability of 10−2.
However, a read in itself is almost useless before it is put into context, either by
assembly, i.e. using overlaps between reads to reconstruct the genome of interest [26],
or by mapping, i.e. aligning reads to a reference, which is the solution of choice when
a reference genome is available [103]. Two major classes of mapping algorithms are
used, either hash-table based (for example Novoalign18 or Stampy [104]), or Burrows
Wheeler transform (BWT)-based (for example BWA [105] or Bowtie [106]). Alignment
methods need to choose a trade-off point between speed and accuracy: hash-table
based methods are usually more accurate, while BWT-based methods are faster [101].
One of the currently most popular mapping algorithms for base-space data is BWA, as
it is fast, freely available, easy to use, and produces reasonably accurate results [45].
After mapping, reads can be sorted into three different categories: unmapped (an
acceptable match was not found in the reference genome), ambiguously or non-uniquely
mapped (several equivalent or nearly equivalent matches were found), or uniquely
mapped. Mapped reads are assigned a mapping quality based on the concordance
between read and reference, and on the underlying base qualities, and this translates
to the probability of misplacing the read. Like the base quality, the mapping quality is
Phred-scaled. Ambiguously mapped reads are assigned a mapping quality of 0 and are
usually not retained for downstream analysis [107]. Mapped reads are usually stored
in standardized BAM (Binary Alignment/Map) files, along with alignment, mismatch
and quality information [108].
Next-generation sequencing experiments are designed to reach a certain mean coverage
or read depth, i.e. a certain redundancy in covering the genome, in order to compensate
for sequencing errors and low allele frequency variants. The more evenly the coverage is
spread across the genome, the more accurate are the analysis results. A mean genomic
coverage of 30x is currently regarded as the standard for variant calling [17,109]. After
alignment, mapped reads are routinely checked for duplicates, i.e. reads with the exact
same 5’ mapping position. These reads arise from a single read during PCR, and
not from different randomly fragmented genomes of multiple cells, as described in the
section ”Known issues” (section 1.1.2). A high number of duplicates is usually due to a
low-complexity library and is to be avoided, as this may introduce unwanted bias and
18http://www.novocraft.com/
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errors. As a consequence, in qualitative sequencing experiments, duplicate reads are
removed after mapping [81,110].
Programming languages and toolboxes used for analysis
The main toolboxes I used for data processing are the command-line based SAMtools
[108] and Picard19 which allow for fast and convenient manipulation of BAM files. All
other computations were performed using the statistical programming language R20,
the high-level programming language Perl21, as well as the Unix scripting language
awk and bash shell scripts [111]. The main scripts are listed in the Technical Annex
(Section 5) at the end of this thesis.
Statistical measures used
Sensitivity and specificity are common statistical terms used to evaluate the perfor-
mance of binary classification [112]. Within this thesis, they were used to evaluate
platform differences in SNP calls. Sensitivity describes the fraction of true positives –
i.e. correctly identified events – among all positive events, i.e. correctly identified and
incorrectly rejected events:
Sensitivity =
TP
TP + FN
TP stands for True Positive, FN for False Negative. Specificity describes the fraction of
true negatives – i.e. correctly rejected events – among all negative events, i.e. correctly
rejected and incorrectly identified events:
Specificity =
TN
TN + FP
TN stands for True Negative, FP for False Positive. Transferred to SNP calling, using
a SNP array as a gold standard, sensitivity is the probability of correctly identifying
an existing array SNP using the next-generation instrument data. Specificity is the
probability of correctly assigning a non-mutated SNP array position using the next-
generation instrument data. Specificity is directly related to the false positive rate:
the higher the specificity, the smaller the false positive rate, i.e. the less incorrectly
identified SNPs we have in the next-generation sequencing data:
False positive rate = 1− Specificity
19http://picard.sourceforge.net/
20http://www.r-project.org/
21http://www.perl.org/
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Similarly, the higher the sensitivity, the smaller the false negative rate, i.e. the less
SNPs we are missing. In addition, ROC (receiver operating characteristic) curves can be
plotted to depict the trade-off between sensitivity and false positive rate under a varying
criterion. The higher the area under the curve (AUC), the better the performance.
1.4 Motivation and thesis outline
In the years 2008 and 2009, due to sharply dropping prices, novel next-generation
sequencing platforms got adopted by a great number of research laboratories world-
wide. Seemingly endless possibilities [6, 113] led to a considerable number of articles
being published in scientific journals. However, as with the launch of every new
technology22, next-generation sequencing came with its own share of teething issues.
Researchers became aware of new biases involved [36, 38, 114] and their likely impact
on next-generation sequencing experiments and analysis results.
Initially, I had been working on data analysis within a project involving the transfer
of a methylation assay to the next-generation sequencing methodology. We were
confronted with a number of unforeseen issues involving an extremely high fraction of
PCR artifacts (sometimes more than 90% duplicate reads), a very uneven distribution
of read numbers between libraries, and some contamination problems. While some
of the problems arising were obviously assay-based, optimization of the methylation
enrichment protocol yielded little overall progress.
This experience sparked the project of benchmarking the different next-generation
sequencing platforms available, evaluating the strengths and weaknesses of each of
them. To this end, we used two tumor-normal pairs from medulloblastoma samples, se-
quenced on the four platforms currently commercially available, Illumina’s HiSeq2000,
Complete Genomics’, and Life Technologies’ SOLiD 4 and 5500xl SOLiD instruments.
I analyzed the data from the four patient samples with regard to the coverage
distribution and biases, in particular GC bias, and I investigated and compared regions
without coverage as well as the coverage of specific genomic regions. In addition, the
potential benefit of a combination of data from different platforms was examined and
SNP calls compared to a gold standard across platforms. Finally, somatic SNVs and
indels were called and compared.
While there are previous publications comparing next-generation sequencing platforms
[115–118], none of them is comprehensive regarding platform choices, and most of them
22http://www.gartner.com/technology/research/methodologies/hype-cycle.jsp
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examine only one sequenced sample. Furthermore, the comparison is usually restricted
to a few aspects only, e.g., SNV calling, and does not include a more in-depth analysis of
genome-wide coverage distribution. The most recent study by Lam et al. [115] analyzes
data from a single healthy subject sequenced with HiSeq2000 and Complete Genomics.
They show that HiSeq2000 is more sensitive in SNV calling than Complete Genomics,
and presume this may be due to HiSeq2000’s longer reads which should lead to a better
coverage of difficult regions. Additionally, they suggest using both technologies as a way
to more comprehensive variant detection, where platform-specific variants are discarded
or additionally validated using another technology.
1.4.1 Publication
I recently published a major part of my results in PLoS One together with my colleague
Marc Zapatka [119].
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2 Methods
Sections 2.1.1 and 2.2.2- 2.2.8 are partly taken from my first-author publication [119].
2.1 Data generation
2.1.1 Whole-genome sequencing
Two tumor/normal pairs obtained from the primary untreated tumor and whole blood
of two pediatric medulloblastoma patients (MB14/BL14, female and MB24/BL24,
male) were sequenced with Complete Genomics, HiSeq2000, SOLiD 4, and 5500xl
SOLiD instruments. Whole-genome sequencing was carried out by the DKFZ Genomics
and Proteomics Core Facility, except for Complete Genomics sequencing, which was
done by the company itself, using their proprietary solution. Run information for each
platform is given in Table 2.1.
All patient material was collected after obtaining written informed consent from partici-
pants and an ethical vote approving the study (Institutional Review Board: Ethics Com-
mittee of the Medical Faculty of Heidelberg University, Germany / Ethikkommission
der Medizinischen Fakulta¨t Heidelberg) according to ICGC guidelines (www.icgc.org).
HiSeq2000
High molecular weight genomic DNA was fragmented in a Covaris instrument (Woburn,
MA, USA) to an average size of 400 nucleotides.
HiSeq2000 library preparation was performed using standard Illumina protocols and
Illumina paired-end adapters. A PhiX kit v2 library (Illumina) was spiked into the
libraries at a proportion of about 1% each. The total loading concentration was 7
pM. Amplification was performed in the cBOT (Illumina) using an Illumina TruSeq
paired-end v2-cluster generation chemistry. For sequencing, 200 cycle TruSeq-v2-SBS
chemistry was used and 2 x 101 cycles of sequencing were performed. Base calling was
performed with Illumina RTA v1.10.36 software.
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Complete
Genomics
HiSeq2000 SOLiD 4 5500xl SOLiD
DNA input
amount
8-16 µg 1 µg 1 µg 1 µg
Read length (bp)
2 x 35
(5+10+10+10)
2 x 100 50+35 75+35
Fragment length
(bp)
∼ 400 400 230 230
Throughput 30-90 GB/day 55 GB/day 5-7 GB/day 20-30 GB/day
Table 2.1: Run information for each platform. Throughput information was obtained
from the manufacturer’s homepage.
SOLiD 4 and 5500xl SOLiD
High molecular weight genomic DNA was fragmented in a Covaris instrument (Woburn,
MA, USA) to an average size of 230 nucleotides.
Genomic libraries were prepared following the manufacturer’s standard instructions.
Emulsion PCRs were performed using SOLiDTMEZ BeadTMSystems. SOLiD 4 sequenc-
ing was performed using Life Technologies standard protocols with 50/35 PE chemistry
and model caller version MCC 4.04. 5500xl SOLiD sequencing was carried out using
75/35 PE chemistry following the manufacturers standard protocols and MCC 5500 1.0
software.
2.2 Data analysis
2.2.1 Hardware
Computations were performed on a high-performance computer cluster with 49 AMD
opteron nodes running under Suse 11.4, each with up to 48 cores. The RAM configu-
ration per node ranges from 16 to 256 GB, and swap space is up to 16 GB, depending
on the node.
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2.2.2 Read mapping
Sequences were aligned to the human reference genome (NCBI build 37/HG19,
released in March 2009), available at http://www.ncbi.nlm.nih.gov/projects/
genome/assembly/grc/human/. Due to the heterogeneous nature of the sequencing
data, e.g., color space for SOLiD 4 and 5500xl SOLiD platforms, or split read structure
for Complete Genomics’ platform (see section 1.1.2), for each sequencer the best
adapted alignment algorithm was used, following the broad experience gained within
DKFZ ICGC projects [110,120,121], as well as personal communication with developers
and application specialists from Life Technologies and Complete Genomics. Alignment
filters were kept as similar as possible. Only uniquely mapping reads were considered.
For HiSeq2000, the reads were mapped by Natalie Ja¨ger (Computational Oncology
Group, Division of Theoretical Bioinformatics, DKFZ) using the Burrows Wheeler
Aligner [105] v0.5.9-r16. For Complete Genomics, due to the specific nature of their
sequencing data and due to their proprietary analysis algorithms, I relied on the
company’s alignment, as further methods were not available. For SOLiD 4 and 5500xl
SOLiD, reads were aligned using Life Technologies’ proprietary Lifescope 2.1 software.
SOLiD 4 reads were aligned by the DKFZ Genomics and Proteomics Core Facility,
5500xl SOLiD reads partly by the Core Facility, partly by myself.
Duplicate reads pairs, i.e. read pairs with identical 5’ coordinates and orientation, were
removed using the Picard software tools v1.61 (http://picard.sourceforge.net/).
2.2.3 Coverage and downsampling
I computed the mean base coverage for each sample and platform after duplicate
removal for all informative bases of the reference genome (excluding Ns) using a custom
python script by Natalie Ja¨ger. For comparison purposes, the BAM files were downsam-
pled by randomly removing read pairs or singletons to reach 30x or 15x mean coverage,
using a custom python script by Marc Zapatka (Division of Molecular Genetics, DKFZ).
Complete Genomics mapping files include reads mapped (”initial mapping files”) and
reads mapped by assembly at candidate regions deviating from the reference (”evidence
files”). To allow for a fair comparison of coverage, only the initial mapping files were
used when downsampling to 30x. For SNP and SNV comparisons, no downsampling
was used, as explained in section 2.2.8.
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Unless otherwise mentioned, all results correspond to 30x mean coverage, or for
Complete Genomics to full coverage generated (for details see Table 2.2). An
evaluation of Complete Genomics at full coverage is included in the analysis because,
as explained in section 1.1.2, in place of selling sequencing instruments as is the
case with Illumina and Life Technologies, Complete Genomics provides a proprietary
sequencing solution with a usually higher coverage (40-80x) including their analysis
of the results, e.g., variant calls. It is therefore not possible to purchase a lower coverage.
Complete
Genomics
HiSeq2000 SOLiD 4 5500xl SOLiD
MB14 45.46x 29.87x 30.0x -
BL14 51.64x 34.06x 30.0x -
MB24 51.76x 34.48x 30.0x 32.51x
BL24 50.0x 33.29x 30.0x 31.0x
Table 2.2: Average coverage information for each sample and platform assessed
2.2.4 Conversion of Complete Genomics data
Complete Genomics uses proprietary formats for their mapping and results files. I
converted the initial mapping files and evidence files to the generic BAM format
[108] using shell scripts and the Complete Genomics Analysis Tools (http://www.
completegenomics.com/analysis-tools/cgatools/) v1.5.0.31, then merged and
position-sorted the resulting BAM files with samtools [108]. Duplicates were removed
using the Picard tool v1.61, as described in section 2.2.2.
2.2.5 Combination of sequencing data from different technologies
For the combination of data from different technologies, both Marc Zapatka and I
merged aligned reads into single BAM files after base quality recalibration with the
Genome Analysis ToolKit (GATK) [122] v1.3 (as described in section 2.2.8).
Marc Zapatka then called variants per chromosome using samtools mpileup and
bcftools with the following command:
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samtools mpileup -R -I -A -B -q 1 -Q $Q -r $chrom -ugf $REF $BAM |
bcftools view -vcgNI - | vcfutils.pl varFilter > result.vcf
Option -A was used to avoid skipping anomalous read pairs during variant calling,
option -B disables Illumina-specific probabilistic realignment. Option -I skips indel
calling. -q 1 skips reads with mapping quality 0, -Q $Q sets the minimum base quality
for a base to be considered, as described in section 2.2.8. $REF stands for the reference
genome. bcftools and vcfutils.pl are used with the standard paramenters.
2.2.6 Coverage distribution and regions without coverage
I computed the per-base coverage and the regions without coverage from BAM files
using samtools mpileup, a custom perl script, and BEDTools [123] v2.14.3. Only
uniquely mapping reads were considered. Reference genome regions composed of
undefined bases (Ns) as well as chr Y were not considered in the analysis.
Unless otherwise mentioned, a base was considered not covered if it was supported
by less than three reads. The rationale behind this cutoff is that we argue 3 reads
are the absolute minimum required to call a heterozygous variant - two reads with a
non-reference base (to exclude sequence artifacts affecting only one read) and one with
the reference base.
Base coverage in 1 kb windows was computed as the sum of the coverage per base using
a custom perl script. GC content in 1 kb windows was computed as the percentage of
GC dinucleotides per bin using custom perl scripts.
2.2.7 Functional regions
BED files with the genomic coordinates for CpG islands, CpG island shores, exons,
segmental duplications, self chains (downloaded on 09/21/2011), promoters, repeats
and mammalian conservation (downloaded on 12/19/2011) were taken from the UCSC
Genome Bioinformatics Site (http://genome.ucsc.edu/).
CpG island shores were defined as 2 kb upstream and downstream of CpG islands [124].
Promoters were defined as 2 kb upstream and 500 bp downstream from the transcrip-
tion start site. Intron coordinates were generated from exon coordinates using custom
perl and shell scripts and BEDTools complementBed and intersectBed. BED files
for different subcategories of repeats were generated by splitting the UCSC repeats file
according to repeat type (DNA repeats, LINE, low complexity repeats, LTR, RC, RNA
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repeats, rRNA, satellites, scRNA, simple repeats, SINE, snRNA, srpRNA, tRNA)
using a custom R script. The coordinates for the Cancer Gene Census (downloaded on
05/31/2011) and genes from the Cosmic database [125] (downloaded on 11/09/2011)
are taken from the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk/).
Overlaps of regions without coverage with the genomic regions mentioned above, as
well as the size of these overlaps, were computed with custom perl and shell scripts and
with BEDTools intersectBed, sortBed, and mergeBed.
2.2.8 SNV calling
To increase base quality accuracy, Marc Zapatka and I performed base recalibration
on HiSeq2000, SOLiD 4, and 5500xl SOLiD data, using the CountCovariates and
TableRecalibration functions within the Genome Analysis ToolKit (GATK) [122]
v1.3.
SNV calling was then done by Marc Zapatka using samtools v0.1.18 for HiSeq2000,
SOLiD 4, and 5500xl SOLiD data. For SOLiD 4 and 5500xl SOLiD data, we were
advised by Life Technologies to use samtools instead of their own analysis software
LifeScope. Lifescope 2.1 was still used in addition. However, samtools yielded a better
concordance with the Affymetrix SNP6 array used as a gold standard, improving the
sensitivity for detecting SNPs identified by the array by one percent while gaining
0.02% in false positive rate.
Complete Genomics performed sequencing and data analysis using their proprietary
pipeline (Software v2.0.1.5). Because the Complete Genomics Analysis Pipeline is not
publicly available, it was not possible to downsample the entire data for direct SNV
comparison.
For the validation of calls with an independent technology, the Affymetrix GenomeWide
Human SNP Array 6.0 was used, which includes more than 906,600 SNPs. The arrays
were hybridized and analyzed by The Centre for Applied Genomics (TCAG) in
Toronto, Canada, according to the standard manufacturer protocols, as described
in [126]. Briefly, the restriction enzymes NspI and StyI (New England Biolabs, Boston,
MA) were used to digest 500ng of genomic DNA, which was then ligated to universal
adapters and amplified using PCR. The resulting digested and amplified DNA was
purified using polystyrene beads, then fragmented with DNaseI, labeled with biotin,
and hybridized to the array. Arrays were then washed on Affymetrix fluidics stations
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and scanned with the Gene Chip Scanner 3000 7G. Quality control was done within
the Affymetrix Genotyping Console (GTC) using the recommended Affymetrix QC
guidelines.
The array genotyping results were used by Marc Zapatka as the gold standard for
the generation of receiver operating characteristic (ROC) curves for each of the four
NGS platforms, using coverage at the SNP position as the independent variable.
Samtools mpileup was used with the following settings, generating vcf files [127] split
by chromosome ($chrom): -AE was used for HiSeq2000 data (using Illumina-specific
probabilistic realignment), -AB for SOLiD and Complete Genomics data. Several
quality cutoffs were tested ($Q: 1 and 13) and the cutoff selected that provided the
largest AUC for the comparison with the SNP6 array.
For HiSeq2000, additional arguments were:
samtools mpileup -R -I -A -E -q 1 -Q $Q -r $chrom -ugf $REF $BAM |
bcftools view -vcgNI - | vcfutils.pl varFilter > result.vcf
and for the SOLiD platforms and Complete Genomics the following command was used:
samtools mpileup -R -I -A -B -q 1 -Q $Q -r $chrom -ugf $REF $BAM |
bcftools view -vcgNI - | vcfutils.pl varFilter > result.vcf
2.2.9 Detection of somatic SNVs
Complete Genomics
Complete Genomics already provides a comprehensive list of variation with every
cancer genome they sequence, which includes somatic variations, called with a
proprietary algorithm adapted to the structure of their data. For reasons stated above
(see sections 2.2.2, 2.2.3), and after having consulted company experts, I relied on their
somatic calls.
Somatic SNV calls were extracted from Complete Genomics’ somaticVcfBeta file,
which contains the full list of genomic variation, using quality criteria fixed according to
Complete Genomics’ Cancer Pipeline user manual (http://media.completegenomics.
com/documents/DataFileFormats+Cancer+Pipeline+2.0.pdf) and with the assis-
tance of the company’s application specialists. I wrote a custom perl script retaining
only the variants matching the following criteria:
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• SNVs with somatic status SS=Somatic
• no VQLOW flag (stands for low call quality)
• a somatic score CGA SOMS > -10 (stands for a high-confidence somatic variant)
The somatic SNVs chosen accordingly were converted to the generic vcf format with
a custom perl script, and then annotated with the genomic categories described in
section 2.2.7 using BEDTools intersectBed and a custom perl script.
HiSeq2000
For somatic SNV calling on HiSeq2000 data, I adapted an in-house calling pipeline
written by Natalie Ja¨ger, Matthias Schlesner and Barbara Hutter (Computational
Oncology group, Division of Theoretical Bioinformatics, DKFZ) to the data. The
pipeline uses publicly available software tools in combination with custom scripts and
filtering steps.
SNVs were first called in the tumor samples using samtools mpileup and bcftools [108],
taking into account only high quality reads and bases (minimum mapping quality: 30;
minimum base quality: 13). Tumor samples often contain variants with a very small
allele frequency due to contamination with normal tissue, copy number variation, and
tumor heterogeneity [110]. To avoid missing these variants, bcftools parameters in the
pipeline were adjusted so that one high quality non-reference base suffices for reporting
a variant (parameter -p 2).
The ensuing high number of false positive SNV calls was corrected using different
filters. The pipeline excluded positions covered by less than three reads in both tumor
and control, with a somatic allele frequency below 5%, or with only one read containing
the variant. Additionally, positions with strand bias, i.e. with reads supporting the
variant found on one strand only, were screened, as this usually indicates a sequencing
error. Bases in the immediate vicinity (+/- 10 bases) of these calls were checked for
Illumina-specific error profiles [34] and the SNVs excluded if a match was found.
A pileup was then generated in the corresponding normal samples at the positions
of the remaining SNV calls. These were divided into germline and somatic events
according to the pileup information. An SNV was categorized as somatic if at most
one read supporting the mutation per 30 reads was found in the corresponding normal
sample.
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Somatic SNVs were then annotated with the genomic categories described in
section 2.2.7 using BEDTools intersectBed and a custom perl script.
SOLiD 4 and 5500xl SOLiD
SNVs were called in the tumor samples using both LifeScope 2.1., Life Technologies’
proprietary analysis software, and samtools with the parameters described above for
HiSeq2000. However, as the calling parameters were extremely lenient, even after
filtering, samtools yielded a number of somatic SNVs so high (8 to 18 times more
than for the corresponding HiSeq2000 samples) that I chose to proceed with LifeScope
calls only and slightly more stringent quality parameters in order to take advantage of
dibase encoding and to avoid an increased number of false positives.
LifeScope SNV calling parameters were fixed to a minimum mapping quality of 30 and
a minimum base quality of 26. Since SOLiD 4 and 5500xl SOLiD have many regions
with low coverage, a minimum coverage of 10 was required for SNV calls. Additionally,
LifeScope computes a p-value for each SNV called. SNVs with a p-value higher than
0.05 were excluded. Finally, SNVs with an allele frequency below 5%, with only one
read containing the variant, or with reads supporting the variant found on one strand
only, were excluded. The resulting files were converted to the generic vcf format with
a custom perl script.
As described above for HiSeq2000, a pileup of the normal sample was then used to
identify somatic SNVs, and the somatic SNVs were then annotated with the genomic
categories described in section 2.2.7 using BEDTools intersectBed and a custom perl
script.
Validation
For each set of somatic SNVs called, I additionally removed all those called as germline
in any of the technologies. Since resources for validation were limited, I chose the 13
somatic SNVs called by all four technologies, as well as, for each platform, 10 to 15
high-quality somatic SNVs that were called for this platform only. The chosen somatic
SNVs were externally validated by Sanger sequencing.
2.2.10 Detection of somatic indels
Indel calling for HiSeq2000 was performed by Qi Wang (Computational Oncology
Group, Division of Theoretical Bioinformatics, DKFZ). Indel calling for SOLiD 4 and
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5500xl SOLiD, and indel extraction for Complete Genomics was done by myself. The
subsequent somatic indel calling was performed by Qi Wang using her own custom shell
and python scripts.
HiSeq2000
Indels were called in the tumor sample using the two-sample model from Pin-
del [128], an algorithm to detect insertions and deletions from paired-end short reads.
Pindel was preferred to samtools because it allows to call larger indels (insertions:
1-20 bp; deletions: 1bp-10kb), which makes its results more comparable to those
obtained for SOLiD 4 and 5500xl SOLiD using LifeScope, and those provided
by Complete Genomics (both calling indels up to 50 bp, according to personal
communication with Life Technologies and to the Complete Genomics FAQ, http:
//www.completegenomics.com/FAQs/Variant-Calls-SNPs-and-Small-Indels/).
The Pindel output was converted to vcf and compared to the pileup of the control
sample using a custom script. A somatic indel was called when at least two reads
supporting the indel were identified in the tumor sample, and no evidence of the indel
was found in the control sample. We required a minimum coverage level of at least
3 reads in control for the position to be considered. The region around the indel
(+/- 10 bp) was then scanned for its deviations from the reference. Regions with
more than one indel or with a mismatch density - computed over all reads - higher
than the average error rate of 0.01 (as assessed by the PhiX control kit, see also the
HiSeq2000 User Guide, http://support.illumina.com/documents/documentation/
System_Documentation/HiSeq2000/HiSeq2000_User_Guide_15011190_P.pdf) were
considered too error-prone and excluded. Insertions corresponding to homopolymers
of length > 5 were also excluded as they are known to have a high error rate [129].
Complete Genomics
Somatic indel calls were extracted from Complete Genomics’ somaticVcfBeta file using
the same procedure as described for somatic SNVs in section 2.2.9, ”Detection of somatic
SNVs”.
SOLiD 4 and 5500xl SOLiD
Indels were called with LifeScope 2.3 using the small indel pipeline. Indels with reads
supporting the variant found on one strand only were filtered out, the filtered results
were then converted to the generic vcf format using a custom perl script. Somatic indels
were then called as described above for HiSeq2000.
36
2.3 Data access
Validation
For each set of somatic indels called, all those called as germline in any of the tech-
nologies were removed. For validation, the only somatic indel called for all four tech-
nologies was chosen, as well as two somatic indels called both on HiSeq2000 and 5500xl
SOLiD, two somatic indels called both on HiSeq2000 and Complete Genomics, and,
for HiSeq2000, Complete Genomics and 5500xl SOLiD, 6 to 10 somatic indels called
for this platform only. The chosen somatic indels were externally validated by Sanger
sequencing.
2.2.11 Statistical tests
For the pairwise platform comparisons of GC bias, I used Kolmogorov-Smirnov tests for
GC percentages below 25% and above 60%. Coverage input values were sampled from
the loess curves. For the comparison of the coverage distribution between platforms,
and for the comparison between platforms of the fraction without coverage for specific
genomic regions, I used two-sample Students t-tests. For the comparison of the ROC
curves, Marc Zapatka focused on the sensitivity, comparing the sensitivity between
different technologies and samples with paired two-sample Student’s t-tests.
Differences yielding p-values below or equal to 0.05 were considered significant. No
p-values were computed for 5500xl SOLiD because of the small sample size (two
samples).
2.3 Data access
All short-read sequencing data have been deposited at the European Genome-phenome
Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under
accession number EGAS00001000274. The Affymetrix SNP6 array data has been
deposited at Array Express (http://www.ebi.ac.uk/arrayexpress/) under accession
number E-MTAB-1159. The main scripts used for this study are listed in the
Technical Annex (Section 5) at the end of this thesis.
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Sections 3.1- 3.4 are partly taken from my first-author publication [119]. The analyses
were performed using the sequenced whole-genome data from two medulloblastoma
tumor-normal pairs, MB14/BL14 and MB24/BL24. The samples were sequenced with
the four technologies assessed in this study, HiSeq2000, SOLiD 4, 5500xl SOLiD, and
Complete Genomics. Unless otherwise mentioned, all results correspond to 30x mean
coverage, or for Complete Genomics to full coverage generated. Complete Genomics
data is included both at full coverage and at downsampled 30x coverage, because they
provide a proprietary sequencing solution with a usually higher coverage (40-80x)
including their analysis of the results. It is not possible to purchase a lower coverage.
In the first part of this comparison, I assess how evenly the reads from every platform
are spread across the genome. A sample’s coverage level and distribution are crucial
for its analysis, as this can introduce considerable bias into the results, even more so
in tumor samples, where contamination with normal tissue, copy number variation,
and tumor heterogeneity can heavily influence variant allele frequency. For each of the
four technologies and for each of the patient samples, I analyzed the read distribution
with respect to the GC content of the underlying sequence (section 3.1), the general
genome-wide distribution of coverage levels (section 3.2), as well as the coverage in
specific genomic regions, like exons or CpG islands (section 3.3), and the size and
fraction of regions without coverage (section 3.4). In addition, I examined whether
a combination of reads from two different platforms can lead to a better coverage of
certain genomic or functional regions (section 3.3).
We further investigated the differences between platforms in sensitivity and specificity
of SNV calling, first by comparing SNV calls from platforms and from combinations of
platforms to the results of a SNP array (sections 3.5 and 3.6). Then I called somatic
variations in the cancer samples and analyzed the overlaps between platforms. A
validation with Sanger sequencing experiments was performed (section 3.7). The SNP
calling analysis in sections 3.5 and 3.6 was mainly conducted by Marc Zapatka (DKFZ),
the somatic indel calling analysis in section 3.7.2 was mainly conducted by Qi Wang
(DKFZ). These results are included here for completeness.
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3.1 GC bias
As explained in section 1.1.2, the GC bias describes the dependence between coverage
and GC contents, where both GC-rich and GC-poor regions are less well covered than
regions with balanced base composition. Ideally, with no GC bias present, we would
see a uniform distribution of coverage, independent of GC content. Figures 3.1 - 3.4
show the genomic coverage per 1 kb interval for each platform, sorted by GC content
of that interval. Each figure corresponds to one of the patient samples.
A one-sample Kolmogorov-Smirnov test confirms that the data from each of the
platforms significantly deviates from the uniform distribution, i.e. a GC bias is found
for every platform. Resulting p-values for patient sample MB24 range between 4.4e-07
and 6.5e-12. To test for significant differences between platforms, I used two-sample
Kolmogorov-Smirnov tests for low (≤ 25% GC content per 1 kb bin) and high (≥ 60%)
GC contents. An overview of the resulting p-values is given in Table 3.1.
Significant differences in GC bias were found between all platforms, except for SOLiD 4
vs. HiSeq2000 for a GC percentage above 60%. The most pronounced GC bias is found
for Life Technologies’ SOLiD 4 and 5500xl SOLiD, especially in regions with more
than 60% GC content. HiSeq2000 shows a slightly reduced GC bias here (significant
in two out of four samples: MB14 and BL14). Note that for HiSeq2000 sequencing, v2
chemistry was used for of all four samples. However, the latest release of v3 chemistry
does not reveal a dramatic reduction in GC bias compared to the earlier v2 chemistry,
as can be seen in Figure 3.5. The least GC bias for GC-rich regions by far is revealed
by Complete Genomics, even when the higher mean coverage of around 50x (hereafter,
”Complete Genomics”) is computationally reduced to 30x mean coverage (hereafter,
”Complete Genomics 30x”) for comparison reasons.
At regions with GC content lower than 25%, 5500xl SOLiD and HiSeq2000 perform
similarly with a generally lower bias than SOLiD 4 and Complete Genomics. In contrast
to its behavior in GC-rich regions, Complete Genomics performs worst in GC-poor
regions at downsampled 30x coverage. The GC bias at GC-rich and GC-poor regions,
respectively, was consistently found across all four sequenced samples, except for patient
sample BL14 where HiSeq2000 and Complete Genomics 30x perform similarly: the
p-values of the Kolmogorov-Smirnov test are 0.9307 for %GC ≤ 25% and 0.4755 for
%GC ≥ 60%, as listed in Table 3.1.
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Figure 3.1: GC bias for each platform for sample MB24. Log2 base coverage in
1kb windows versus GC content in percent is shown for HiSeq2000,
SOLiD 4, 5500xl SOLiD, and Complete Genomics data. The first panel
shows an overlay of all four technologies. The upper right panel shows
HiSeq2000 only (blue), the lower left SOLiD 4 and 5500xl SOLiD (red and
orange, respectively), and the lower right Complete Genomics at full and
downsampled 30x coverage (green and light green). Smoothed loess curves
are fitted to each dataset to represent the local coverage trend.
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Figure 3.2: GC bias for each platform for sample BL24, plotted analogously to
Figure 3.1.
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Figure 3.3: GC bias for each platform for sample MB14, plotted analogously to
Figure 3.1. 5500xl SOLiD data is available only for samples MB24/BL24
(see Table 2.2).
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Figure 3.4: GC bias for each platform for sample BL14, plotted analogously to
Figure 3.1. 5500xl SOLiD data is available only for samples MB24/BL24
(see Table 2.2).
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% GC in 1 kb
bin ≤ 25%
% GC in 1 kb
bin ≥ 60%
HiSeq2000 - CG 30x
MB14 0.00217 0.01484
BL14 0.9307 0.4755
MB24 0.00217 0.03561
BL24 0.00217 0.03561
HiSeq2000 - SOLiD 4
MB14 0.474 0.00561
BL14 0.02597 0.03561
MB24 0.00217 0.0779
BL24 0.00217 0.1558
CG 30x - SOLiD 4
MB14 0.00217 3.352e-08
BL14 0.02597 0.00016
MB24 0.00217 3.964e-05
BL24 0.00217 0.00016
Table 3.1: P-values from Kolmogorov-Smirnov tests for pairwise platform comparisons
of GC bias. CG 30x stands for Complete Genomics downsampled to 30x
mean coverage. P-values below 0.05 are highlighted in bold and italic.
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Figure 3.5: GC bias for HiSeq2000 with v2 chemistry versus HiSeq2000 with v3
chemistry. Log2 base coverage in 1kb windows is plotted versus GC content
in percent. Smoothed loess curves are fitted to each dataset to represent
the local coverage trend, analogously to Figure 3.1. Exemplary data from
patient sample MB24 (v2, blue) is compared to another medulloblastoma
patient sample (v3, red).
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3.2 Coverage distribution
Looking at the genome-wide distribution of coverage levels, a number of striking
differences between platforms can be seen (Figure 3.6). The most obvious divergence
appears between Life Technologies’ platforms, SOLiD 4 and 5500xl SOLiD, on one side,
and HiSeq2000 and Complete Genomics on the other. At the same mean coverage,
SOLiD 4 and 5500xl SOLiD show about 6 times more bases supported by less than
5 reads compared to HiSeq2000 and Complete Genomics. While the latter two show
similar numbers in this respect, downsampling Complete Genomics to 30x for fairness
of comparison shows a mean increase of almost factor 2.5 in bases supported by less
than 5 reads. An average of these numbers across all samples is given in Table 3.2.
Coverage distribution is similar for Life Technologies’ platforms SOLiD 4 and 5500xl
SOLiD, with 5500xl SOLiD showing a slightly higher number of bases with higher
coverage (20-60x). HiSeq2000 shows by far the narrowest coverage distribution
compared to all other sequencing platforms, meaning its coverage is the most evenly
distributed across the genome. Complete Genomics has the broadest coverage
distribution, i.e. the highest deviations from the mean. Even for Complete Genomics
downsampled to 30x mean coverage, the coverage distribution is still wider than the
one resulting from HiSeq2000.
The cumulative coverage distribution, i.e. the percentage of the genome covered with
at least n x, is shown in Figures 3.7 to 3.9, with Figure 3.7 showing the distribution
for all samples and all platforms, Figure 3.8 showing the distribution of the sample
means for each platform, and Figure 3.9 showing a magnified view of the sample
means. These reveal that 5500xl SOLiD covers the smallest percentage of the genome,
while HiSeq2000 and SOLiD 4 cover a similar and slightly higher fraction. However,
the fraction of the genome covered for all three platforms is exceeded by Complete
Genomics at both 30x and full coverage.
Further, higher variations in coverage distribution can be observed between the different
samples sequenced by Complete Genomics compared to the other platforms, with the
fraction of the genome covered with at least 30x differing up to about 15%, and even
up to about 18% for the fraction of the genome covered with at least 50x (Figure 3.7).
This is probably largely due to the differences in average coverage between Complete
Genomics samples (see Table 2.2), but the between-sample variation can still be
observed to a slightly lesser extent for low cumulative read depth at downsampled
30x coverage.
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Figure 3.6: Distribution of genome-wide base coverage for each of the four platforms.
Complete Genomics is shown at full coverage and at downsampled 30x
coverage. Each curve corresponds to one sample.
Figure 3.7: Percentage of genome covered by a given read depth. Each curve corresponds
to one sample. The colors used correspond to the legend in Figure 3.6. The
inset on the upper right shows a magnified view of the curves.
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Figure 3.8: Mean percentage of genome covered by a given read depth. Each curve
corresponds to the mean of all samples sequenced by one technology.
Figure 3.9: Magnified view of the mean percentage of genome covered by a given read
depth as depicted in Figure 3.8. Each curve corresponds to the mean of all
samples sequenced by one technology.
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Complete
Genomics
Complete
Genomics 30x
HiSeq2000 SOLiD 4 5500xl SOLiD
Total number
of bases
covered
2,826,524,353 2,817,003,995 2,801,114,390 2,795,379,490 2,772,621,192
Number of
bases
covered with
less than 5
reads
15,938,617 38,555,229 17,727,532 100,145,774 99,297,132
Table 3.2: Number of bases covered on average across all samples, and average number
of bases covered with less than five reads, for each platform assessed.
3.3 Coverage of genomic regions
To further evaluate the coverage differences between the different platforms, I analyzed
the coverage in specific genomic and functional regions. Here, bases covered by fewer
than three reads were considered as ”not covered” or ”without coverage”, as explained
in section 2.2.6.
Each of the four technologies has its strengths and weaknesses in covering different
sections of the genome (Figure 3.10). Complete Genomics shows a similar coverage
fraction for almost all regions, with a generally very low percentage (< 2%) of bases
not covered, both at 30x coverage and at full coverage. A comparably smaller covered
fraction is observed only for regions containing a large number of short repeats, like
simple repeats (24% uncovered at 30x coverage), low complexity repeats (11.9%), CpG
islands (9.2%), and satellite repeats (3.7%). Overall, Complete Genomics performs
better than all other technologies in this respect, except for simple repeat regions
where it is surpassed by all three other platforms.
Comparative coverage of an exemplary simple repeat region is shown in Figure 3.11 (a).
Almost no reads are mapped to this region by Complete Genomics. Read pairs with
reads mapping to different chromosomes can be observed for HiSeq2000, SOLiD 4 and
5500xl SOLiD sequences, which reflects the difficulty of mapping reads to repeated
sequences also for the latter three technologies. Interestingly, SOLiD 4 shows the
highest coverage in this example, but also the largest number of differences from the
reference genome.
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Figure 3.10: Mean percentage of uncovered bases across different genomic elements for
each of the platforms. Bases covered with less than three reads were
considered not covered. Note that reducing this threshold to 1 does not
dramatically change the overall distribution of reads (see Figure 3.12).
Error bars represent one standard deviation as obtained from analyzing
all samples sequenced on one platform. DNA, LINE, Low complexity,
LTR, RC, RNA, Satellite, Simple repeats and SINE are subcategories of
Repeats (all). For better visibility, CpG islands, low complexity and simple
repeats are plotted separately.
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Figure 3.11: Visualization of read coverage for two exemplary genomic regions from
patient sample MB24 by IGV [130] for HiSeq2000, SOLiD 4, 5500xl SOLiD
and Complete Genomics. (a) A simple repeat region on chr1:267,289-
267,425. (b) A CpG island on chr1:713,984-714,547.
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Figure 3.12: Mean percentage of uncovered bases across different genomic elements for
each of the platforms. In this case, a base is considered not covered when it
is covered by zero reads. The error bars represent one standard deviation
as obtained from analyzing all samples sequenced on one platform. DNA,
LINE, Low complexity, LTR, RC, RNA, Satellite, Simple repeats and SINE
are subcategories of Repeats (all). For better visibility, CpG islands, low
complexity and simple repeats are plotted separately.
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SOLiD 4 and 5500xl SOLiD sequencing are most affected by GC content and
consequently have by far the largest percentage of bases not covered in CpG islands
(58.2% and 52.5%, respectively) and CpG island shores (7.5% and 7%, respectively).
A t-test yields a p-value of 0.00069 (HiSeq2000 vs. SOLiD 4) and 0.0008 (Complete
Genomics 30x vs. SOLiD 4) for CpG islands and a p-value of 0.019 (HiSeq2000 vs.
SOLiD 4) and 0.01 (Complete Genomics 30x vs. SOLiD 4) for CpG island shores.
For all platforms except for Complete Genomics, the fraction of CpG islands without
coverage roughly doubles through our definition of an uncovered base (compare to
Figure 3.12), showing that a large proportion of these regions is covered by less than 3
reads.
Coverage of an exemplary CpG island is shown in Figure 3.11 (b). Complete Genomics
shows an impressive coverage of this region followed by HiSeq2000. The lowest coverage
is present in SOLiD 4 and 5500xl SOLiD data.
Concordant with the differences in coverage of CpG regions, the exome coverage also
shows dramatic differences between platforms with a mean difference in the fraction
of bases not covered of factor 6.6 between Complete Genomics at 30x and SOLiD 4
(p-value 0.006). Overall, HiSeq2000 performs better than SOLiD 4 and 5500xl SOLiD
in nearly all categories except for satellite regions (p-value 0.005 HiSeq2000 vs. SOLiD
4), and even outperforms Complete Genomics (both at full and at 30x coverage) in
simple repeat regions (p-value 0.0386). SOLiD 4 performs slightly better than 5500xl
SOLiD in repeat regions, while 5500xl SOLiD shows better coverage than SOLiD 4 in
most other regions.
Interestingly, at the same mean 30x coverage, a combination of HiSeq2000 with 5500xl
SOLiD data considerably decreases the uncovered fraction of certain repeat regions for
both technologies, especially in satellites and simple repeats (Figure 3.13 (a) and (b)).
Similarly, a combination of Complete Genomics data at full coverage with as little as
15x HiSeq2000 data (typically obtained with only one sequencing lane) shows a major
increase of covered bases in simple repeats (Figure 3.13 (b)).
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Figure 3.13: Mean fraction of uncovered bases across genomic elements for different
combinations of technologies. Error bars represent one standard deviation
as obtained from analyzing all samples in the group. (a) Mean fraction
of uncovered bases for chosen repeat regions. Performance is compared
to sequence data from single technology platforms. Only regions with
observable differences are displayed. (b) Mean fraction of uncovered bases
across simple repeat regions for different combinations of technologies. CG
stands for Complete Genomics.
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3.4 Regions without coverage
While the number of uncovered regions is similar for all platforms for larger-sized
regions of 150 bp and above (see Figure 3.14), Life Technologies’ platforms SOLiD
4 and 5500xl SOLiD show very high numbers of small regions without coverage
compared to HiSeq2000 and Complete Genomics. The smaller the regions, the more
pronounced are the differences between platforms, with HiSeq2000 performing better
than Complete Genomics. 5500xl SOLiD shows slight improvement over SOLiD 4,
except for extremely small regions of 1-2 bp, where the slight difference increases to
a factor of 1.5 in the number of uncovered regions: on average, 384,304 uncovered
regions of 1-2 bp are found for SOLiD 4, versus 260,252 regions for 5500xl SOLiD.
The size of the largest region without coverage is approximately 110,000 bp for all four
platforms, except for HiSeq2000 whose largest region is 766,173 bp in length. However,
this is due to the pseudoautosomal region on chromosome X and Y [131] and is a
consequence of mapping differences: reads belonging to this region cannot be uniquely
mapped to a reference genome containing the region on both chromosome X and Y
and thus were automatically discarded before analysis (see section 2.2.2).
The fraction of the genome left without coverage (based on the reference genome
excluding N’s) at 30x coverage for HiSeq2000 and downsampled Complete Genomics
is very similar (1.45% versus 1.61% on average across samples), both performing
approximately 2.5 better in this respect than SOLiD 4 and 5500xl SOLiD. At 15x
coverage, the difference between HiSeq2000 and the Life Technologies platforms is even
more marked with a factor of approximately 3.5, suggesting that the latter can catch
up at higher coverage. Notably, Complete Genomics at full coverage leaves only an
average of 0.79% of the genome not covered.
3.5 SNP calling
After closely assessing coverage differences between the different technologies, we
followed up with the identification of SNVs and the performance of the platforms in
this respect. SNV calling is one of the major aims of sequencing projects, especially in
cancer research.
To this end, Affymetrix SNP6 arrays were used as a gold standard for all samples.
Affymetrix arrays are a sequencing-independent, well-established SNP calling
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Figure 3.14: Size distribution of regions without coverage for all platforms and all
samples, based on the reference genome excluding N’s. Each curve
corresponds to one sample. A base is considered uncovered when it is
covered by less than three reads, as described in section 2.2.6. The x-axis
is truncated at 200 bp.
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technology1. To ensure that only minimal bias is introduced by the genomic positions
assayed by the arrays, the distribution of array SNPs in different areas of the genome
was examined. Figures 3.15 and 3.16 show an overview of the results.
Introns and regions of mammalian conservation show a similar representation on the
SNP array and on the genome, and a high fraction of the regions contain at least one
array SNP. Promoters, exons and CpG island (CGI) shores show a percentage of array
SNPs similar to their fraction of the genome size. However, a large fraction of those
regions does not contain SNPs measured on the array. Within CpG islands (covering
0.76% of the genome) the percentage of array SNPs (0.037%) is even a lot lower than
expected from the size of CpG islands. Still, this corresponds to 1283 array SNPs
falling into this genomic region, allowing a reasonable evaluation of the sequencing
performance.
Repeat regions (Figure 3.16) show a similar representation on the SNP array and on
the genome for most repeat types. Only SINEs are underrepresented (genome 27.1%,
array SNPs 14.8% equivalent to 44659 SNPs), as are simple repeats, low complexity
regions and satellite regions. However, this still results in a high number of array
SNPs falling into these regions (respectively 1100, 374 and 758 array SNPs for simple
repeats, low complexity regions and satellite regions).
Receiver operating characteristic (ROC) curves were computed for each platform and
sample, as explained in section 2.2.8, to show the sensitivity and false positive rate
(equivalent to 1 - specificity) for SNV calling, using the Affymetrix SNP6 array as
a reference (Figure 3.17 - 3.24). This SNP calling sensitivity should be considered an
upper bound for somatic mutation calling, as cancer samples usually involve variant
allele frequencies far below 50% (see section 1.2.3).
229 out of 907,551 SNPs, i.e. 0.025%, were not found on any of the four platforms,
which may indicate that these SNPs are false positives on the SNP array. Looking at
the ROC curves, the best platform in terms of sensitivity is HiSeq2000 (e.g., 99.15%
for patient sample MB24, Figure 3.17 and 3.18), followed by Complete Genomics
(e.g., 98.38% sensitivity for patient sample MB24). A t-test on sensitivity over
all samples yields a p-value of 0.008651 for HiSeq2000 versus Complete Genomics.
Notably, HiSeq2000 needs far less overall coverage than Complete Genomics to reach
a comparable sensitivity: even at downsampled 15x coverage, HiSeq2000 reaches a
1http://media.affymetrix.com/support/technical/other/snp6_array_publications.pdf
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Figure 3.15: Percentage of genome covered by different genomic elements, in comparison
to the distribution of Affymetrix array SNPs on these genomic elements,
for patient sample MB24.
sensitivity of, e.g., 98.12% for patient sample MB24.
At the positions assayed by the SNP array, Complete Genomics shows a mean coverage
considerably lower than its genome-wide mean coverage, while HiSeq2000 performs
close to its overall mean coverage in this respect. E.g., for Complete Genomics on
patient sample MB24, the SNP array positions are covered with 40x on average, versus
51.7x overall, while HiSeq2000’s SNP array positions are covered with 32.1x. However,
this still does not account for the fact that HiSeq2000 at 15x and Complete Genomics
show a similar SNP calling sensitivity.
5500xl SOLiD and especially SOLiD 4 show a strongly reduced sensitivity in most
samples. E.g., 5500xl SOLiD has a sensitivity of 96.80% on patient sample MB24,
while SOLiD 4 reaches only 92.57% on the same sample. A t-test on all samples
between SOLiD 4 and HiSeq2000 yields a p-value of 0.008324, and of 0.008189 between
SOLiD 4 and Complete Genomics. However, this reduced sensitivity comes with a
slightly lower false positive rate compared to HiSeq2000 (approximately 0.105-0.124%
on patient sample MB24 for SOLiD 4 and 5500xl SOLiD, respectively).
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Figure 3.16: Distribution of Affymetrix array SNPs in repeat types analyzed for patient
sample MB24. The percentage given in the upper panels for the size of
each repeat region was computed in relation to the size of all genomic
repeats. The percentage of array SNPs shown in the lower panels for
specific repeat regions was computed in relation to the number of array
SNPs in all genomic repeats.
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Figure 3.17: ROC curves comparing sensitivity and specificity of SNV calling for all
platforms on sample MB24. The false positive rate (1 - specificity) is
plotted from 0-0.15. All curves have reached their plateau at that point
and will continue as straight lines.
Figure 3.18: Magnified view of the ROC curves for sample MB24 as indicated by the
dashed frame in Figure 3.17. Curves that do not appear in this plot reached
their plateau below the sensitivity cutoff chosen for this window.
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Figure 3.19: ROC curves for SNV calling on patient sample BL24, plotted analogously
to Figure 3.17.
Figure 3.20: Magnified view of ROC curves for SNV calling on patient sample BL24,
plotted analogously to Figure 3.18.
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Figure 3.21: ROC curves for SNV calling on patient sample MB14, plotted analogously
to Figure 3.17.
Figure 3.22: Magnified view of ROC curves for SNV calling on patient sample MB14,
plotted analogously to Figure 3.18.
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Figure 3.23: ROC curves for SNV calling on patient sample BL14, plotted analogously
to Figure 3.17.
Figure 3.24: Magnified view of ROC curves for SNV calling on patient sample BL14,
plotted analogously to Figure 3.18.
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3.6 Combination of sequencing technologies
Additionally, we assessed whether combining sequencing data from different
technologies would improve SNV calling results, uniting the strengths and compensating
for the weaknesses of each platform. As expected, combining the data sets as they
are, and thus reaching a coverage twice as high, e.g., with HiSeq2000 at 30x plus
5500xl SOLiD at 30x, yields a sensitivity and specificity slightly higher than any other
technology alone (Figure 3.18).
However, when comparing SNV results at a similar coverage, i.e. with a combination of
platforms at a total coverage of 30x, it is hardly possible to reach a sensitivity higher
than the one achieved with HiSeq2000 sequencing alone. This result can be confirmed
on all samples (see Figures 3.20, 3.22, and 3.24). Combining HiSeq2000 with 5500xl
SOLiD data, at 15x each, yields good results. The sensitivity decreases only slightly
compared to HiSeq2000 at full coverage, and specificity slightly increases above the
level reached by 5500xl SOLiD. However, the decrease in sensitivity (0.17%) is far
higher than the increase in specificity (0.0025%).
An interesting result is that for Complete Genomics sequencing, adding HiSeq2000
data at only 15x, a coverage that currently corresponds to only one lane of HiSeq2000
sequencing, can improve the SNV calling performance of Complete Genomics both in
sensitivity and specificity. The increase in sensitivity reached here is 0.73% compared
to Complete Genomics alone, which corresponds to a p-value of 0.008692, at a slightly
increased specificity.
3.7 Somatic variation calling
Going beyond the calling of SNVs within one sample, we attempted to estimate the
performance of the different platforms in cancer genome studies by calling somatic SNVs
and somatic indels on the two tumor/normal pairs, MB14/BL14 and MB24/BL24.
3.7.1 Somatic SNVs
After calling somatic SNVs as described in section 2.2.9, I first examined the overlap
between platforms. An overview of the number of somatic SNVs called for each
technology is given in Table 3.3. Generally, patient sample MB14 seems to contain
more somatic SNVs than MB24. However, it is striking to see that, for one and
the same sample, these numbers are extremely different between platforms, ranging
from 71 somatic SNVs on SOLiD 4, to 1599 on Complete Genomics for sample
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pair MB24/BL24. In addition, the between-sample ratio also varies a lot between
technologies, with 18.8 times more somatic SNVs found in patient sample MB14 (1333)
than in sample MB24 (71) for SOLiD 4, while the ratio is 6.8 for HiSeq2000 and only
1.7 for Complete Genomics. As we know from other studies of the same samples that
MB24 is tetraploid [110], this indicates that the platforms differ in their ability to pick
up variants with low allele frequency.
HiSeq2000 SOLiD 4
5500xl
SOLiD
Complete
Genomics
MB14 3950 1333 - 2962
MB24 584 71 470 1599
Table 3.3: Number of somatic SNVs called for each sample, for each of the four
technologies.
The pairwise overlap of somatic SNVs between platforms is shown in Figure 3.25 and
3.26. In addition, the number of somatic SNVs called by all four platforms concordantly
is only 456 for MB14 and only 13 for MB24. These numbers are drastically below any
expectation. If anything, the concordance is a bit better for sample MB14, even though
the number of somatic SNVs called is higher than in MB24.
Comparison to validation experiments
To further investigate the reasons for the drastic lack of overlap between somatic
SNVs on different platforms, I had the opportunity to have a small number of SNVs
externally validated with Sanger sequencing. For validation, variants from patient
sample MB24 were chosen in order to include 5500xl SOLiD in the comparison, and
because this sample seems to contain fewer somatic SNVs than sample MB14.
The 13 somatic SNVs that were concordantly called by all four technologies were
selected for Sanger validation, as well as, for each platform, 10 to 15 somatic SNVs that
were not called on any other platform, preferentially those called with high confidence.
An overview of validation results is given in Table 3.4. The individual variants and their
validation status are listed in Tables 3.5 (concordant SNVs selected for validation), 3.6
(HiSeq2000), 3.7 (SOLiD 4), 3.8 (5500xl SOLiD), and 3.9 (Complete Genomics). The
reason why the number of SNVs validated is different for each platform is that some
of the PCR reactions for validation failed.
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Figure 3.25: Overlap of somatic SNVs called by different technologies. The left-hand
side panels stand for patient sample MB14, the right-hand side panels for
patient sample MB24.
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Figure 3.26: Overlap of somatic SNVs called by different technologies for patient sample
MB24.
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Concordant 9/9 true somatic changes
HiSeq2000 only 2/7 true somatic changes
SOLiD 4 only 0/14 true somatic changes
5500xl SOLiD only 0/11 true somatic changes
Complete Genomics only 1/9 true somatic changes
Table 3.4: Somatic SNV results: number of true somatic changes out of the total number
tested, as validated by Sanger sequencing.
The validation results show that we can be confident that a variant called by all
platforms is real: all variants that could be tested are true somatic changes. However,
variants called by one platform only have disastrous validation rates: only 1 out of 9
variants could be validated for Complete Genomics and only 2 out of 7 for HiSeq2000,
while not even a single somatic SNV called by either SOLiD 4 or 5500xl SOLiD was
true. If we extrapolate, this would mean that most platform-specific somatic SNV calls
are false.
Subsequently, I examined the true and false somatic SNVs in order to understand why
these variants were only picked up by one technology.
SOLiD ”flanking SNV” artifact
The most obvious cause for false positive somatic SNVs can be seen in Life Technologies’
platforms and is a consequence of color space SNV calling (see section 1.1.2). Figure 3.27
illustrates what we call the ”flanking SNV” artifact: the false positive somatic SNV is
flanked by two SNVs positioned on either side. In Life Technologies’ color space, SNVs
are discriminated from sequencing errors through dibase encoding: each base is linked
to each of its neighbors by a common color code, which results in a certain number of
valid dicolor changes relative to the reference, corresponding to SNVs. Any deviation
from these changes is considered a sequencing error [22,132].
However, the event of an SNV followed by a reference base followed by a second SNV,
as depicted in Figure 3.27, results not in two, but in four subsequent colors differing
from the reference. This means that even though the base in the middle is a reference
base, it is represented by two colors differing from the reference (the second and third
color changes) and is therefore considered as an SNV. This assumption, in turn, renders
the first and the last of the four color changes, which correspond to the flanking real
SNVs, invalid: the false call of an SNV between the real SNVs has already reverted
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Figure 3.27: An example of the ”flanking SNV” artifact seen in Life Technologies’ plat-
forms. This is an IGV screen shot for SOLiD 4 and patient sample MB24.
the real SNVs to reference bases.
These false calls in the tumor are not filtered out during somatic SNV calling, as
the comparison to the normal sample is based on a pileup in base space and not on
color space. Since there is no mutation at the corresponding position in the normal
sample, the SNV in the tumor is considered somatic, although it is simply falsely called.
A closer look at the somatic SNVs called in Life Technologies’ platforms, beyond those
chosen for validation, shows that this is their main source of error. For SOLiD 4,
10 out of 14 somatic SNVs that were Sanger-validated (71,4%) and 21 out of the 31
remaining (67,7%) result from this artifact. For 5500xl, 8 out of 11 somatic SNVs that
were Sanger-validated (72,7%) carry the artifact, and out of 27 further somatic SNVs
checked manually, 16 carry it (59,3%). This means that roughly 2/3 of the somatic
SNVs called in Life Technologies’ platforms are false positives generated by a calling
issue.
Other technologies
The next question addressed was why the three platform-specific somatic SNVs that
were confirmed by Sanger sequencing (1 on Complete Genomics, 2 on HiSeq2000, as
listed in Table 3.4) were not picked up by the other technologies.
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The two confirmed HiSeq2000-specific variants have a rather low allele frequency (0.2
and 0.22, respectively). They are actually initially identified as somatic by Complete
Genomics, but with an extremely low probability score (flagged as SQLOW), which is
why they are filtered out. On the SOLiD platforms, the first variant is actually visible
in the tumor BAM file on IGV, but is not called, probably because of the low allele
frequency. The second variant is not visible in the SOLiD BAMs due to low coverage
of the region.
The confirmed Complete Genomics-specific variant is also initially identified in
HiSeq2000, but is later filtered out because it lies within a sequence region containing
the Illumina-specific error pattern GGC [34]. On the SOLiD platforms, the variant
is visible in the tumor BAM on IGV, but is not called, which may be due to the low
allele frequency (0.24).
In summary, the three Sanger-confirmed platform-specific somatic SNV calls are
generally hard to call because of low allele frequency, or because the region they fall
in which may not be covered well enough in SOLiD platforms, or contains a known
Illumina error pattern.
A closer look at the false somatic SNVs assessed by Sanger sequencing also reveals
miscellaneous and sometimes unclear reasons for their call. Very often, the SNVs
are located in regions that are difficult to map to, like poly-A stretches or segmental
duplications. Another reason for falsely called somatic SNVs are mutations that are
also present in control, but are not called because the coverage or the allele frequency
are too low. Finally, a few cases seem to be sequencing errors, where a mutation can
clearly be seen in the tumor BAM file on IGV, even though the Sanger validation could
not identify any.
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chr pos dbSNP ref alt genomic regions
hom/
het
validation
result
chr1 172157950 - A G
Introns
Mammal conservation
Promoters
LINE repeats
het confirmed
chr1 237345250 - C T
Introns
Mammal conservation
het confirmed
chr3 7589499 - C T
Introns
Mammal conservation
het confirmed
chr3 14882459 rs116407913 G A
Introns
Mammal conservation
het
sequencing
failed
chr3 106758969 - A G
Mammal conservation
LINE repeats
het
sequencing
failed
chr4 594999 - G C
Mammal conservation
LINE repeats
Self chain
het confirmed
chr6 108328601 - C T
Mammal conservation
Promoters
LTR Repeats
het
sequencing
failed
chr7 109072602 - T A
Mammal conservation
LINE Repeats
het
sequencing
failed
chr8 27427015 - G A Mammal conservation het confirmed
chr9 9216163 - C T
Introns
Mammal conservation
SINE Repeats
het confirmed
chr12 28477282 - A G
Introns
Mammal conservation
Promoters
het confirmed
chr15 39798057 - C A Mammal conservation het confirmed
chr16 9975836 - G A
Introns
Mammal conservation
het confirmed
Table 3.5: Overview of the somatic SNVs concordant between all four platforms
and their Sanger sequencing validation results. For each somatic SNV
the chromosome, position, dbSNP identification (if present), reference and
alternative allele, genomic regions, zygosity and Sanger validation result is
given.
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chr pos dbSNP ref alt genomic regions
hom/
het
validation
result
alt. allele
frequency
chr1 43754699 - G T
Mammal conservation
Promoters
LINE repeats
het TRUE 0.22
chr2 114188440 - C T
Introns
Mammal conservation
Promoters
LTR repeats
Segmental duplication
Self chain
hom FN 0.83
chr4 23622862 - A C Simple repeats hom FP 1
chr6 33747921 - G A
Exons
Mammal conservation
Promoters
het TRUE 0.2
chr9 68380340 rs77836632 G T
CpG islands
Mammal conservation
Segmental duplications
Self chain
het FP 0.24
chr19 4512945 rs75031432 C T
Exons
Mammal conservation
het FN 0.27
chr19 4512946 rs79662071 A G
Exons
Mammal conservation
het FN 0.27
Table 3.6: Overview of the HiSeq2000 somatic SNVs chosen for Sanger validation, and
their validation results. For each somatic SNV the chromosome, position,
dbSNP identification (if present), reference and alternative allele, genomic
regions, zygosity, Sanger validation result, and alternative allele frequency
is given. ”False positive” (FP) stands for an SNV that was not found in
the tumor with Sanger sequencing, ”false negative” (FN) for an SNV that is
found both in tumor and control with Sanger sequencing.
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chr pos dbSNP ref alt genomic regions
hom/
het
validation
result
alt. allele
frequency
chr1 106238081 - T G
Mammal conservation
LINE repeats
het
Flanking SNV
artifact
0.46
chr3 19041671 rs112827577 T A Mammal conservation het
Flanking SNV
artifact
0.32
chr5 11008475 rs113518426 T C
Introns
Mammal conservation
Promoters
LTR repeats
het
Flanking SNV
artifact
0.44
chr6 29819600 - G A
CGI shores
Mammal conservation
Self chain
het
Flanking SNV
artifact
0.24
chr7 53857155 - G A Mammal conservation het
Flanking SNV
artifact
0.47
chr7 152104381 rs113774675 A G
Introns
Mammal conservation
Self chain
het
Flanking SNV
artifact
0.4
chr9 6932312 rs112868579 G A
Introns
Mammal conservation
het
Flanking SNV
artifact
0.33
chr12 31826443 - G A
Introns
Mammal conservation
Promoters
LINE repeats
het
Flanking SNV
artifact
0.36
chr13 102878420 - G A
Introns
Mammal conservation
het
Flanking SNV
artifact
0.26
chr15 21183913 rs115553418 T C
Mammal conservation
Promoters
Segmental duplications
Self chain
het FN 0.36
chr15 85114547 rs12899953 T C
CGI shores
Mammal conservation
Promoters
Segmental duplications
Self chain
Simple repeats
het FN 0.5
chr21 9907222 - T C
CGI shores
Introns
Mammal conservation
Segmental duplications
Self chain
het FN 0.29
chr22 47384036 rs113412201 A G
Introns
Mammal conservation
DNA repeats
het
Flanking SNV
artifact
0.28
chr22 49544337 rs6009515 T A
Mammal conservation
Self chain
het FP 0.43
Table 3.7: Overview of the SOLiD 4 somatic SNVs chosen for Sanger validation, and
their validation results. For each somatic SNV the chromosome, position,
dbSNP identification (if present), reference and alternative allele, genomic
regions, zygosity, Sanger validation result, and alternative allele frequency is
given. ’False positive’ stands for an SNV that was not found in the tumor
with Sanger sequencing, ’false negative’ for an SNV that is found both in
tumor and control with Sanger sequencing.
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chr pos dbSNP ref alt genomic regions
hom/
het
validation
result
alt. allele
frequency
chr1 16842448 rs3982351 G A
CGI shores
Mammal conservation
Segmental duplications
Self Chain
het FP 0.25
chr3 10168966 rs113587531 T C
Mammal conservation
Promoters
het
Flanking SNV
artifact
0.32
chr8 69145468 rs34931257 A G
Mammal conservation
Promoters
het
Flanking SNV
artifact
0.53
chr8 125315212 - A T
CGI shores
Mammal conservation
Segmental duplications
Self chain
het
Flanking SNV
artifact
0.45
chr10 105356443 - C G
Introns
Mammal conservation
Promoters
Simple repeats
het
Flanking SNV
artifact
0.32
chr16 33942851 rs76303220 C A
CpG islands
Mammal conservation
Segmental duplications
Self chain
het FP 0.38
chr16 78921414 - A G
Introns
Mammal conservation
Simple repeats
het
Flanking SNV
artifact
0.54
chr17 31963897 rs111564603 C A
Introns
Mammal conservation
Self chain
Simple repeats
het
Flanking SNV
artifact
0.42
chr17 76253591 - G A
Mammal conservation
Promoters
Simple repeats
het FN 0.55
chr19 52099247 - C T
CGI shores
Mammal conservation
Promoters
LINE repeats
Self chain
het
Flanking SNV
artifact
0.29
chr20 6065730 rs112086590 T C
Exons
Mammal conservation
het
Flanking SNV
artifact
0.4
Table 3.8: Overview of the 5500xl SOLiD somatic SNVs chosen for Sanger validation,
and their validation results. For each somatic SNV the chromosome, position,
dbSNP identification (if present), reference and alternative allele, genomic
regions, zygosity, Sanger validation result, and alternative allele frequency is
given. ’False positive’ stands for an SNV that was not found in the tumor
with Sanger sequencing, ’false negative’ for an SNV that is found both in
tumor and control with Sanger sequencing.
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chr pos dbSNP ref alt genomic regions
hom/
het
validation
result
alt. allele
frequency
chr1 17322619 - A G
Exons
Mammal conservation
het FP 0.21
chr1 36907562 - C A
Introns
Mammal conservation
Promoters
SINE repeats
het FP 0.21
chr1 47076668 - A C
CGI shores
Introns
Mammal conservation
het FP 0.21
chr3 100170628 - A G
Exons
Mammal conservation
het FN 0.2
chr4 166199389 - T A
Exons
Mammal conservation
Segmental duplications
Self chain
het FN 0.34
chr10 129905945 - T G
Exons
Mammal conservation
Self chain
het FP 0.21
chr15 102226182 - C T
Exons
Mammal conservation
het TRUE 0.24
chr17 16876781 - G A
Mammal conservation
Promoters
LINE repeats
Self chain
het FP 0.27
chr20 61595238 - T G
Introns
Mammal conservation
Promoters
het FP 0.21
Table 3.9: Overview of the Complete Genomics somatic SNVs chosen for Sanger
validation, and their validation results. For each somatic SNV the
chromosome, position, dbSNP identification (if present), reference and
alternative allele, genomic regions, zygosity, Sanger validation result, and
alternative allele frequency is given. ’False positive’ stands for an SNV that
was not found in the tumor with Sanger sequencing, ’false negative’ for an
SNV that is found both in tumor and control with Sanger sequencing.
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3.7.2 Somatic indels
The overall number of somatic indels (Table 3.10) shows that, similarly to the somatic
SNVs, the differences between platforms are pronounced. Most variations are called
in HiSeq2000 (966), followed by 5500xl SOLiD (630), Complete Genomics (457) and
finally SOLiD 4 (37). However, the ratio between insertions and deletions is rather
similar for HiSeq2000, 5500xl SOLiD and SOLiD 4, ranging from 0.56 for HiSeq2000 to
0.72 for 5500xl SOLiD, which is consistent with the fact that insertions are generally
harder to call than deletions [129]. For Complete Genomics however, this trend is
reversed: for 333 insertions called in patient sample MB24, only 124 deletions are found.
The overlap between platforms, both for insertions and for deletions, is even lower than
for somatic SNVs (Figure 3.28). Generally, SOLiD 4 seems to have absolutely no indels
in common with the other platforms, while only one deletion and zero insertions are
shared by the three other platforms. The number of somatic insertions or deletions
shared by two platforms is slightly higher (e.g., 4 deletions and 18 insertions for
Complete Genomics and HiSeq2000, and 3 deletions and 4 insertions for Hiseq2000
and 5500xl SOLiD), but still represents only an extremely tiny fraction of the total
number of indels per platform.
HiSeq2000 SOLiD 4 5500xl SOLiD CG
MB24
ins 346 15 265 333
del 620 22 365 124
Table 3.10: Number of somatic indels called for patient sample MB24, for each of the
four technologies. ”ins” stands for insertion, ”del” for deletion. CG stands
for Complete Genomics.
Comparison to validation experiments
We had the opportunity to have a small number of somatic indels from patient sample
MB24 externally validated with Sanger sequencing. The 5 indels that were identified
on more than one platform were selected for validation (see Table 3.15), as well as
7 to 10 indels called by one technology only (Tables 3.12 (HiSeq2000), 3.13 (5500xl
SOLiD), and 3.14 (Complete Genomics)). An overview of the results of the Sanger
validation can be found in Table 3.11.
As expected, indels called on at least two different technologies are real, whereas not a
single one of those called by a single platform could be confirmed by Sanger sequencing.
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This suggests that indel calling is not very accurate, regardless of technology, and that
somatic indel calling is an even bigger challenge. Indeed, for HiSeq2000, SOLiD 4, and
5500xl SOLiD, the majority of platform-specific indels assessed by Sanger sequencing
are false negatives, meaning the indel was found in control, making it a germline indel.
This is different for Complete Genomics, which has a majority of false positive indels
among those assessed by Sanger sequencing, i.e. of indels found neither in the tumor
nor in the control. This indicates that the predominant difficulty lies in the calling of
somatic indels for all platforms except Complete Genomics, which seems to call many
false positive indels overall.
Figure 3.28: Overlap of somatic insertions and deletions found across platforms for
patient sample MB24. The plot includes platform-specific somatic SNVs
called as germline by other platforms.
HiSeq2000 + 5500xl SOLiD + CG 1/1 true somatic changes
HiSeq2000 + 5500xl SOLiD 2/2 true somatic changes
HiSeq2000 + CG 2/2 true somatic changes
HiSeq2000 only 0/9 true somatic changes
5500xl SOLiD only 0/7 true somatic changes
CG only 0/10 true somatic changes
Table 3.11: Somatic indels results: number of true somatic changes out of the total
number tested, as validated by Sanger sequencing. CG stands for Complete
Genomics.
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chr pos ref alt allele frequency validation result
chr1 26895673 AAG A 0,2 False negative
chr1 54429616 G GC 0,4 False negative
chr2 96657159 C CG 0,364 False negative
chr2 201929338 ATTAT A 0,111 False negative
chr4 171115658 AC A 0,136 False negative
chr10 127595259 G GA 0,162 False positive, or allele freq too low
chr11 20499360 CA C 0,3 False negative
chr15 77246836 GGA G 0,125 False negative
chr18 15322955 ATTTATAC A 0,091 False positive
Table 3.12: Overview of the HiSeq2000 somatic indels chosen for Sanger validation, and
their validation results. For each somatic indel the chromosome, position,
reference and alternative allele, allele frequency and Sanger validation result
is given. ’False positive’ stands for an indel that was not found in the tumor
with Sanger sequencing, ’false negative’ for an indel that is found both in
tumor and control with Sanger sequencing.
chr pos ref alt allele frequency validation result
chr1 143475780 ACCAATTTTGT ACCAATTTGT 0,545 False negative
chr2 132776038 AAGACTCTAG AAGACTAG 0,333 False negative
chr5 115202417 CTAAGAGA CTGA 0,057 False positive, or allele freq too low
chr7 8010576 TA TAT 0,071 False negative
chr15 20083350 AC ACTTAC 0,116 False negative
chr15 20942204 TTCAACCATACAT TTCAACAT 0,389 False negative
chr21 31123516 TATG TATGTG 0,077 False positive, or allele freq too low
Table 3.13: Overview of the 5500xl SOLiD somatic indels chosen for Sanger validation,
and their validation results. For each somatic indel the chromosome,
position, reference and alternative allele, allele frequency and Sanger
validation result is given. ’False positive’ stands for an indel that was not
found in the tumor with Sanger sequencing, ’false negative’ for an indel that
is found both in tumor and control with Sanger sequencing.
chr pos ref alt allele frequency validation result
chr1 247104579 CAAA C 0,308 False negative
chr2 228593117 TGCG T 0,291 False positive
chr5 3125712 T TTGTTGTTGTTTGTTTCTTTTTGTTGTTGA 0,625 False positive
chr6 160956039 A ATGATGGTGGTAG 0,292 False positive
chr10 134326339 A ACTGAGCCCTACTCTCATCCCCAACGACCCAGG 0,731 False positive
chr14 24522271 GCA G 0,333 False negative
chr16 6773733 A AT 0,258 False negative
chr19 5852410 CT C 0,187 False positive, or allele freq too low
chr22 16202448 A AC 0,346 False positive
chr22 48930058 A
ACATGAATAAGTCAGGTGC
GGTGGGTCAGGCAGGTGC
0,433 False positive
Table 3.14: Overview of the Complete Genomics somatic indels chosen for Sanger
validation, and their validation results. For each somatic indel the
chromosome, position, reference and alternative allele, allele frequency and
Sanger validation result is given. ’False positive’ stands for an indel that
was not found in the tumor with Sanger sequencing, ’false negative’ for an
indel that is found both in tumor and control with Sanger sequencing.
79
3 Results
chr pos ref alt allele frequency validation result
platforms
found in
chr5 39297910 GA G 0,147 Confirmed HiSeq2000, 5500xl SOLiD
chr11 123375285 TC T 0,143 Confirmed HiSeq2000, 5500xl SOLiD
chr3 967815 TC T 0,171 Confirmed HiSeq2000, Complete Genomics
chr4 82373501 TG T 0,129 Confirmed HiSeq2000, Complete Genomics
chr18 730060 GTTTAA G 0,176 Confirmed HiSeq2000, 5500xl SOLiD, Complete Genomics
Table 3.15: Overview of the somatic indels found by several platforms that were chosen
for Sanger validation, and their validation results. For each somatic indel
the chromosome, position, reference and alternative allele, allele frequency,
Sanger validation result and platforms found on is given. ’False positive’
stands for an indel that was not found in the tumor with Sanger sequencing,
’false negative’ for an indel that is found both in tumor and control with
Sanger sequencing.
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The recent advent of massively parallel sequencing technologies has paved the way to
a better assessment and thus a better understanding of genomics and genetics. Once
an extremely costly and time-intensive task, large-scale human genome sequencing is
only a few steps away from becoming a routine laboratory task. However, the state-of-
the-art platforms currently available are still relatively new and thus not thoroughly
evaluated, and there are a number of caveats to be considered and uncovered.
The goal of this thesis is a comparison of the four whole-genome sequencing instruments
currently established on the market: Illumina’s HiSeq2000, Life Technologies’ SOLiD 4
and 5500xl SOLiD, and Complete Genomics’ technology. To this end, I used four
whole-genome samples (two tumor-normal pairs) from two pediatric medulloblastoma
patients, sequenced once on each of the four platforms. For each sequencing machine,
I presented an extensive assessment of coverage distribution and bias, in particular GC
bias, a comparison of SNV calls with regard to a SNP array gold standard, as well
as an assessment of the potential benefits of combining mapped reads from different
technologies. Additionally, somatic mutation calls (SNVs and indels) from different
platforms were evaluated. This study highlights the advantages and drawbacks of the
individual platforms while considerably extending previous comparative studies, as it
includes all four platforms, uses a more comprehensive approach, and assesses multiple
samples instead of one, allowing more compelling results.
4.1 Coverage assessment
Coverage, i.e. the redundancy with which each base in the sequenced genome is
covered, should ideally be evenly distributed across the genome. Instead it fluctuates
substantially due to different factors [133], one of the most common being the
underlying base or sequence composition. An even and sufficient coverage of all
genomic regions is crucial for reliable downstream analysis for a number of reasons.
First, it minimizes the impact of sequencing errors: unless it is a systematic error
due, for example, to a specific sequence pattern [34], the same sequencing error
is highly unlikely to appear at the same genomic position in many different reads
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(although the overall number of sequencing errors, assuming a constant error
rate, increases with coverage). As a consequence, the higher the coverage, the
higher is the confidence in the results of a downstream analysis. A mean coverage of
30x is currently agreed as the standard for whole-genome sequencing (see section 1.3.2).
In addition, sufficient coverage is essential for accurately calling variants with low
allele frequency. These are extremely common in cancer samples, due to tumor
heterogeneity, tissue heterogeneity, and copy number variations (see section 1.2.3).
Localized lack of coverage or extremely low coverage, regardless of the reason, may lead
to the downstream analysis missing or erroneously reporting important variants, while
fluctuating coverage is an issue particularly in quantitative sequencing experiments like
RNA-seq, ChIP-seq, or CNV-seq. Coverage biases are often found in specific genomic
regions of interest, like in GC-rich or GC-poor regions, which are often located in or
near genes and gene promoters, or in repeat regions which may have a number of
different functions, as explained in section 1.1.2.
My results show that GC bias, i.e. a significant drop in coverage in GC-rich, but
also GC-poor regions, is present in all samples and for all platforms analyzed, but is
most pronounced for SOLiD 4 and 5500xl SOLiD instruments, in particular in regions
with a GC content above 60%. A slightly better coverage of GC-rich regions can be
observed with HiSeq2000, but the least (although present) GC bias is achieved with
Complete Genomics. This is in contrast to GC-poor regions (≤ 25% GC content),
where Complete Genomics shows the highest deviation from a uniform distribution,
together with SOLiD 4, while HiSeq2000 and 5500xl SOLiD exhibit a substantially
better coverage. This confirms results from earlier studies [38, 117] which clearly show
the presence of a GC bias in several next-generation sequencing platforms, notably
in data from Illumina’s GAII instrument, but stands in contrast to the results from
Suzuki et al. [116] who claim finding ”no striking GC bias” for SOLiD sequencers.
The overall coverage distribution proved to be surprisingly diverse, with HiSeq2000
showing the narrowest peak, i.e. the most even distribution. All three other platforms,
when observed at comparable coverage levels, display a relatively high number of bases
with very low (< 5) coverage. In addition, between-sample variation for Complete
Genomics was shown to be higher than for other technologies, even at similar mean
coverage, therefore hampering a comparison of variant calls between samples, as variant
call sensitivity is related to coverage. Also, up to a cumulative coverage of around 40x,
Complete Genomics covers a smaller genome fraction compared with HiSeq2000 at the
same mean coverage. This is consistent with Lam et al.’s remark that the less uniform
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the coverage, the higher mean coverage is needed to reach a certain read depth level
for most of the genome [115].
There is also major variation between sequencers in the uncovered fraction of specific
genomic and functional regions, the most striking being in CpG islands. Consistent
with the GC bias mentioned above, both SOLiD 4 and 5500xl SOLiD have major
difficulties covering CpG islands, leaving over half of them uncovered. This offers a
straightforward explanation for the major difficulties encountered in the analysis of
data from methylation experiments described in section 1.4, as these were conducted
on the SOLiD 4 platform. Also, a large part of CpG islands is covered with less
than 3 reads for both HiSeq2000 and the SOLiD sequencers, although HiSeq2000
performs better in this respect than its predecessor, Illumina’s GAII [117]. The good
performance of Complete Genomics might seem counter-intuitive, as CpG islands
contain a high number of repeated sequences, and Complete Genomics’ read length is
by far the shortest of all four platforms. However, as exemplified by Benjamini and
Speed [38], the GC bias is dependent on the GC content of the full fragment and not
just the sequenced read. Complete Genomics’ complex protocol uses short fragmented
sequences interspersed with adapter sequences, therefore lowering the GC content of
the fragment and making it less susceptible to GC bias.
Generally, Complete Genomics, even at downsampled 30x coverage, shows the smallest
uncovered fractions for most genomic regions considered, although it is usually closely
followed by HiSeq2000. Its weakness lies in the coverage of short repeats, in particular
simple repeats, which is most likely due to the shortness and split structure of the
reads, as the other technologies perform better in this respect. This also fits with the
observation of Lam et al. [115] that, compared to concordant SNVs, a high fraction of
platform-specific SNVs are located within simple repeats and low complexity repeats,
suggesting that these false positive calls are due to mapping difficulties.
Overall, it is the SOLiD 4 and 5500xl platforms which display the most shortcomings,
SOLiD 4 even more than 5500xl, often leaving considerable fractions of genomic
elements not covered. Exon coverage, which is of paramount importance in sequencing,
is particularly problematic in this respect, with around 10-12% of uncovered bases for
the SOLiD sequencers.
A combination of mapped reads from two different sequencers, as proposed by Nothnagel
et al. as an attempt to lower the false positive rate for SNV calling [118], showed limited
improvement in the uncovered fractions of problematic regions. The attempt to combine
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the strengths of two platforms in this respect proved to be useful for only few of the
genomic regions considered, in particular specific repeat regions.
4.2 Variant detection comparison
SNVs called genome-wide were compared to the SNP calls obtained from Affymetrix
arrays, which were used as a gold standard to compute sensitivity and false positive
rate. HiSeq2000 consistently reaches the highest sensitivity on all samples, closely
followed by Complete Genomics, even though the mean coverage for HiSeq2000 is
considerably lower than Complete Genomics’ coverage. In fact, even with half the
coverage, i.e. 15x, HiSeq reaches a sensitivity very close to Complete Genomics at
full coverage. It is interesting to note that Complete Genomics’ coverage at the SNP
positions assessed is substantially lower than the sample’s mean coverage (e.g., 40x vs.
51.7x for patient sample MB24), while this is not the case for HiSeq2000. Still, this
does not justify that HiSeq2000 at 15x reaches the sensitivity of Complete Genomics
at full coverage. The sensitivity of 5500xl SOLiD, and SOLiD 4 in particular, is far
behind the sensitivity reached by HiSeq2000 and Complete Genomics, although the
specificity is slightly increased.
The comparison of reliability of concordant and discordant SNV calls conducted by
Lam et al. on HiSeq2000 and Complete Genomics data [115] shows results consistent
with our findings. An earlier study by Suzuki et al. [116] mentions similar detection
performance for Illumina and SOLiD platforms, but these result relate to data from
very early sequencing machines (Illumina’s Genome Analyzer and SOLiD’s first
platform). Altogether, the results denote a strong preference for Complete Genomics
and HiSeq2000 in any research setting focusing on sensitive yet specific results. This is
especially valid for cancer research which relies on the detection of variants with low
allele frequency.
A combination of mapped reads from two different technologies shows that the
sensitivity reached by HiSeq2000 is hard to outperform. The sensitivity of 5500xl
SOLiD data can be strongly increased by combining 15x coverage from this machine
with 15x coverage from HiSeq2000, at the cost of a small loss of specificity, but will
not reach the sensitivity of HiSeq2000 alone. Interestingly however, the sensitivity of
Complete Genomics calls can be significantly increased by adding as little as one lane
(corresponding to around 15x mean coverage) of HiSeq2000 sequencing. This supports
the suggestion by Lam et al. [115] that combining sequence data from different platform
can help boosting their strengths for SNV calling.
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4.3 Evaluation of the detection of somatic mutations
As evidenced in section 1.2.3, calling somatic mutations in cancer samples is a
challenging task for a number of reasons. The cells of tumor tissues can contain very
heterogeneous genomes, the samples are usually admixed with a certain amount of
normal tissue, and copy number variation and polyploidy occur frequently, the latter
being a common event in pediatric medulloblastoma patients [110]. All this leads to a
low allele frequency (i.e., below 50%) for many somatic mutations, meaning that there
may be only a handful of reads carrying the mutation of interest, and that these need
to be distinguished from sequencing errors. This emphasizes once again the importance
of sufficient coverage (section 4.1).
In addition, somatic variation is identified by comparing the sequenced tumor sample
to the sequence of a normal, unaffected control sample. This holds an additional
source of error, since many false positive calls in the tumor sample will result in a
somatic mutation call, as we are unlikely to find the exact same error in control. This
means that, regardless of their origin, a large part of the false positive calls within the
tumor will be kept when calling somatic SNVs. Because there are usually few somatic
mutations in comparison to the total number of mutations called – i.e., germline and
somatic –, the fraction of false positive calls increases when moving on to somatic
calling. This is particularly evident for the ”flanking SNV” artifact I identified within
SOLiD data (see section 3.7.1) which affects a drastic 2/3 of SOLiD’s somatic SNV
calls, but it is to be expected that this factor will also affect the other platforms,
although to a lesser extent.
Besides false positive somatic mutation calls, comparison to a control normal tissue also
introduces false negative calls, i.e. germline mutations that are picked up in the tumor
sample but missed in the control, for example due to a low allele frequency and/or
low coverage, low base quality or mapping quality, or strand bias. Taken together, all
three factors mentioned above – low allele frequency in cancer samples, false positive
calls stemming from sequencing errors, and false negative calls – increase the error rate
compared to one-sample SNV calling in a non-cancer context, i.e. without classification
into somatic and germline.
The somatic SNV calling results show pronounced differences. The number of somatic
SNVs called varies strongly between platforms on the same sample, as does the
between-sample ratio from platform to platform. Overall, each platform presents more
somatic SNV calls for patient sample MB14 than for patient sample MB24. This is
very probably due to the fact that MB24 is tetraploid, and suggests that the ability to
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detect variants with low allele frequency differs between platforms.
Both the overlap between results from different platforms, and the Sanger validation
rates for somatic SNVs specific to one platform are extremely low, MB14 performing
slightly better in this respect than MB24. While somatic SNVs called by all platforms
were all validated by Sanger sequencing (9 out of 9 tested), none of the SOLiD
4-specific and 5500xl SOLiD-specific somatic SNVs chosen for Sanger resequencing
could be validated (0 out of 14 and 0 out of 11, respectively), and only very few of the
somatic SNVs found exclusively with HiSeq2000 or Complete Genomics sequencing
were actually verified (2 out of 7 and 1 out of 9, respectively). This suggests that using
more than one platform for somatic mutation calling may be beneficial for weeding out
false calls and increasing specificity, as a large majority of platform-specific calls seem
to be false. This is consistent with Lam et al.’s finding on standard mutation calling in
a healthy individual that ”concordant SNVs have high accuracy and platform-specific
SNVs have a high false positive rate” [115], an effect that is intensified for somatic
events.
As mentioned above, a major portion of somatic SNV calls detected with SOLiD
sequencing are false calls arising through the ”flanking SNV” artifact. These make
up not only roughly 2/3 of the total somatic calls, but also around 80-100% of the
number of non-overlapping calls in pairwise platform comparisons, depending on
the instrument used and sample studied. Assuming a low error rate for concordant
calls between two platforms, this supports the conclusions from the SNP comparison
showing a comparatively low false positive rate for the SOLiD platforms.
A closer look at the three Sanger-validated, true platform-specific variants in Complete
Genomics and HiSeq2000 data shows that the main reasons why they were missed in
the other platforms are indeed low allele frequency and/or low coverage, the latter
being a problem especially for the SOLiD platforms with their more variable coverage
distribution. False calls not validated by Sanger sequencing, on the other hand, mostly
fall into the categories of ”false positive” and ”false negative” calls illustrated above,
although they are often found in error-prone regions like homopolymer stretches or
repeats. It is interesting to note that almost all of the Sanger-assessed false calls on
the SOLiD platforms, not considering the ”flanking SNV” artifacts, fall into GC-rich
regions like promoters, CpG islands, and CpG islands shores, which is consistent with
the poor coverage of SOLiD platforms in these regions. The influence of analysis tools
on these results is further discussed in section 4.4.
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4.3.1 Somatic indel calling
Somatic indel calling results show even less overlap between platforms and an even
lower validation rate compared to somatic SNVs. The general issues stated above are
valid for all somatic events, but however, indel calling in itself is already an extremely
challenging task [129, 134]. Indel calling depends very strongly on the abilities of the
mapper to allow gapped alignments, as reads containing indels are more difficult and
less straightforward to map than reads containing base errors or SNVs, especially
in the case of longer insertions. Very often, reads with indels will be mapped with
mismatches instead of a gap, and even with a gapped alignment, the indel may not
be placed at its exact location due to, for example, the presence of repetitive elements
or insufficient quality. Finally, some instruments, including Illumina’s platforms, have
difficulties accurately detecting the length of homopolymers [129].
Indel detection is a topic of current research and is far less advanced than SNV calling
due to its higher complexity. Solutions to the indel issue include, for example, analyses
that do not consider reads independently [134].
4.4 Influence of mapping and detection software
An important point when comparing platforms is acknowledging the influence of the
chosen analysis software on the results, as this is what essentially gives meaning to the
raw data. At first sight, using the exact same software for every platform and every
analysis step may seem like the most straightforward solution for a cross-platform
comparison. However, there are a number of caveats to consider in our case. While
Illumina platforms essentially follow the previously used consensus of a base-by-base
read-out of DNA fragments, both Complete Genomics and the SOLiD platforms
introduce new concepts that require adapted handling of the raw data. Both the use
of color space instead of base space and the use of fragmented reads with interspersed
adapters (see section 1.1.2) hold advantages, like added error correction for SOLiD
through two-base encoding, or a better coverage of GC-rich locations for Complete
Genomics. However, using the same software for all platforms compared will not only
prevent taking advantage of these properties, but will also heavily penalize all platforms
but one. As an example, my experience showed that mapping SOLiD data in base space
results in about 50% to 65% less mapped reads in comparison to mapping in color space.
For this reason, both for mapping and for variant calling, we used the software
tools we consider best adapted for each platform. While we are aware that using
different software choices for different sequencing machines will introduce bias, our
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understanding is that this bias will be considerably smaller than the bias introduced
by using the same options for all sequencers, especially for mapping. Our criteria
for choosing the analysis software include comparison of results (e.g., AUC for ROC
curves), extensive shared experience of several DKFZ research groups on different
types of sequencing data, particularly within ICGC projects [110, 120, 121], personal
communication with experts from Life Technologies and Complete Genomics, published
algorithm comparisons [104, 105, 117, 135], and commonness of use within the next-
generation sequencing community.
For the mapping of reads from Illumina’s HiSeq2000 platform, BWA [105] was used
for a number of reasons. BWA is one of the most widely used mappers for Illumina
data, and also the mapper of choice for ICGC Illumina data. It was shown to have one
of the best overall performances for Illumina data [117], has a good trade-off between
speed and accuracy [135], and is relatively easy and straightforward to use.
For SOLiD data, the mapping algorithm was required to map in color space, which
greatly restricted the available choices. The main options were the LifeScope aligner
by Life Technologies1, NovoalignCS by Novocraft2, BFAST [136], and SHRiMP [137].
BWA and Bowtie [106], which are sometimes stated as color space compatible mappers,
actually dropped their color space support. SHRiMP was rejected as an option due to
its extremely long run times [117], as was BFAST, which has issues with the pairing of
SOLiD reads3,4. NovoalignCS is a commercial mapper and was therefore disregarded.
Although Novocraft offers a version that is free for academic and non-commercial
use, it does not support multithreading, which makes it rather slow in comparison.
LifeScope (previously BioScope) comes with the sequencing machine, and the latest
version is free, meaning most SOLiD data users have access to it. It is the most widely
used SOLiD mapper and was retained as our mapping choice for the SOLiD machines.
There is currently only one aligner which takes the specific nature of Complete
Genomics’ data into consideration - the company’s own proprietary software. None of
the analysis methods routinely used by Complete Genomics are available for use outside
the company, and Complete Genomics does not use any of the established standard
data file formats. In addition, the processes of mapping and calling variants are very
intertwined, as the company uses re-assembly at locations differing from the reference
1http://de-de.invitrogen.com/site/de/de/home/Products-and-Services/Applications/
Sequencing/Next-Generation-Sequencing/Data-Analysis-Solutions-for-Next-Generation-Sequencing/
LifeScope-Genomic-Analysis-Solutions/LifeScope-Genomic-Analysis-Software.html
2http://www.novocraft.com/wiki/tiki-index.php?page=NovoalignCS
3http://sourceforge.net/apps/mediawiki/bfast/index.php?title=Main_Page
4http://www.nilshomer.com/index.php?title=BFAST_with_BWA
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genome. However, one of Complete Genomics’ unique selling points is the inclusion
of an extensive analysis of the generated data, a feature that is useful to customers
lacking the considerable infrastructure and knowledge needed for downstream analysis,
making it even less likely for users to apply their own downstream analysis. For this
reason, Complete Genomics’ analysis results were used, including mapping and variant
calling results. Quality filters were applied to the somatic calls, as advised in personal
communication with company experts.
There is a wide range of available Illumina-centered SNV calling algorithms
based on different methodologies [101], the most commonly used methods being
samtools/bcftools [108] and GATK [122]. As they differ only minimally in methodology,
samtools was used for calling SNVs because it was already established in our group. It
was used for the comparison to the SNP array for both HiSeq2000 and SOLiD data,
as for the latter it improved sensitivity (as computed from the SNP array) by 1% at a
hardly altered specificity, when compared to the results obtained with LifeScope.
For calling somatic SNVs, I had access to a very comprehensive and well-tuned pipeline
that is routinely used in ICGC projects [110]. Except for Illumina-specific filtering
steps, the procedure used after SNV calling for determining the somatic/germline
status of each mutation was kept the same for HiSeq2000 and SOLiD data. Preliminary
results from benchmarking studies5 show that different calling procedures will yield
very different total numbers of somatic SNVs, sometimes differing by an order of
magnitude. This encouraged us to use a setup as similar as possible for HiSeq2000,
SOLiD 4, and 5500xl SOLiD data.
Overall however, it is hardly possible to disentangle the influence of analysis software
choices from the effects of using a particular sequencing platform, as these are often
intricately linked. As an example, lack of sufficient coverage was identified as an
important cause of missed calls, but the reasons for lack of coverage are manifold,
and are often both an issue of the platform and of the downstream analysis: mapping
difficulties can be due to low base or read quality, due to specific sequencing biases, due
to the mappability of the region, due to a short read length, or due to too stringent
alignment settings.
5currently unpublished; talk by Ivo Gut, ICGC meeting, Heidelberg, December 10th, 2012
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4.5 Conclusions and outlook
This comparative study reveals the strong and weak points of the sequencing machines
and provides an indication of the preferred platform to use, depending on the aims
of the experiment. The most striking result is the poor performance of the two
SOLiD sequencers in a GC-related setting, disapproving their use especially for
methylation assessment and exon sequencing. This also explains the major problems
that occurred during the methylation experiments performed with SOLiD 4 machines
(see section 1.4). Combining raw data from different technologies proved to be only
of limited use and is indicated only for very specific applications that require good
coverage of specific genomic regions while retaining high SNP calling sensitivity. The
latter proved to vary strongly between platforms and once again places the SOLiD
platforms, in particular SOLiD 4, at the bottom end. The assessment of somatic
SNVs showed that calling somatic mutations is still a big challenge for many different
reasons. It requires high, and preferably evenly distributed coverage throughout the
genome in order to ease the discovery of mutations with low allele frequency. Using the
calls from several platforms was shown to increase the certitude of a true somatic call.
Comprehensive benchmarking experiments are needed for a better understanding of
the issues raised by somatic calling, a task that is beginning to be tackled by large-scale
sequencing consortia [138].
Laboratory parameters like the required amount of starting DNA, sequencing costs,
or turnaround time, were not considered in this comparison. Although they might be
decisive for choosing a particular sequencing platform, they tend to vary strongly over
time. However, it is worth pointing out that HiSeq2000 currently has by far the fastest
turnaround time among the sequencing machines considered, and that Complete
Genomics requires a comparatively high amount of starting material, prohibiting its
use for experiments with a very limited DNA amount available. Furthermore, there is a
lack of adapted downstream analysis algorithms for Complete Genomics’ data, except
for their own proprietary software, and while the company’s analysis service is useful
for smaller labs without bioinformatics support or strong computational infrastructure,
it is not flexible enough in other cases and does not match with the requirements of a
comprehensive analysis.
Different methods for downstream analysis were explicitly not reviewed here, as this
has already been done, and instead the algorithms best adapted to each platform were
chosen in order to give consideration to the heterogeneity of the data generated by the
different instruments. While a larger sample size per platform would have given more
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statistical power, this is currently difficult to achieve because of budgetary issues.
New, ”third” generation platforms currently emerge, which confirms the trend towards
platforms generating longer reads, a development that will help circumvent many of
the issues encountered with current next-generation sequencing instruments. Once
a sufficient throughput can be obtained, they will compete with current technology.
After the launch of the Ion Proton sequencer, Life Technologies recently promised the
”1000$ genome” in the foreseeable future [139]. Pacific Biosciences is developing the
promising SMRT (single-molecule real-time) sequencing, a technology which offers much
longer reads and less bias, as well as modified base detection (see section 1.1.2). The
throughput is currently too low for human-sized genomes and the error rate is still high,
but these issues are expected to be resolved in the future, opening the field for a more
comprehensive assessment of human genetics and genomics.
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5 Technical annex
The major scripts used for this thesis are included on a CD. A description can be found
below.
Coverage analysis
• coverageQc.py
determines genome-wide coverage
• mpileup.sh
runs samtools mpileup per chromosome, giving coverage for each covered
genomic position
• mpileup coverage distrib.sh
concatenates mpileup single-chromosome files and computes coverage
distribution using mpileup files
• sortn uniqc.py
used by mpileup coverage distrib.sh for coverage computation
• genome coverage plots.R
plots coverage distributions
• generate bed of uncovered regions refgenome.pl
computes coordinates of Ns in reference genome
(used for generate bed of uncovered regions.pl and
generate bed of uncovered regions 0-2.pl)
• generate bed of uncovered regions.pl
generates, for each technology, a BED file of uncovered regions
• generate bed of uncovered regions 0-2.pl
generates, for each technology, a BED file of uncovered regions (meaning, in
this case, base coverage < 3)
• my.genomehg19
chromosome sizes for reference genome version HG19; used by the scripts
above
• run compute uncovered regions overlap with bed files 30x.sh
starts compute uncovered regions overlap with bed files.sh
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• compute uncovered regions overlap with bed files.sh
computes the overlap of uncovered regions with genomic and functional
regions
• compute BED bp size.pl
computes the size of the overlaps (used for
compute uncovered regions overlap with bed files.sh)
• compute uncovered regions overlap with bed files cleanupFiles.sh
concatenates results from
compute uncovered regions overlap with bed files.sh
• xls plot with R.R
plots, for each platform and for each genomic/functional region, the
percentage of the region that is not covered
• xls plot with R functions.R
functions used in xls plot with R.R
• uncovered regions stats 30x.R
plots the size distribution of the regions not covered for each technology
• plot vsGC tumorcontrol.R
plots the GC bias
SNP analysis
• ROC functions.r
identifies concordance between array and the different platforms, computes
and plots ROC values plots
Somatic analysis
• CG somaticSNVsToVcf.pl
conversion of Complete Genomics’ somaticVcfBeta file format to generic vcf
file format
• CG extract somatic SNVs.pl
extracts somatic SNV calls from Complete Genomics calls
• LT filter SNPs gff3.pl and LT diBayesSNP GFF3 2vcf.pl
filtering and conversion from gff3 to vcf file format for LifeScope SNV calls
• LT split converted vcf per chr.pl
splits up LifeScope SNV calls by chromosome
• ./natalie snvcalling/ and ./matthias snvcalling/
somatic SNV calling pipeline
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• CG extract germline SNVs.pl
extracts germline SNVs for Complete Genomics
• filter somaticSNVs by germlinelist alltechs.pl
filters somatic SNVs (removes all those that are called as germline in any
of the technologies)
• overlap concordant discordant snvs 2ndversion.pl
• overlap concordant discordant snvs all4techs.pl
computes somatic SNV overlaps between platforms
• vennDiag concordant discordant.R
plots Venn diagrams of the somatic SNV overlaps between platforms
• discordant somSNVs only 1 tech.pl
computes somatic SNVs called by only one platform
• overlap concordant discordant snvs withfctregions 2ndversion.pl
annotate the somatic SNVs with functional regions
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